Pfenex (PFNX) 10-K16 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 02, 2015	Jul. 24, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	PFNX
Entity Registrant Name	Pfenex Inc.
Entity Central Index Key	1478121
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		20,522,557
Entity Public Float			$45.50

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$45,722	$3,954
Short-term investments		1,250
Accounts and unbilled receivables, net	1,584	3,461
Inventories	23	26
Income tax receivable	402	398
Deferred income taxes	3,281	3,481
Other current assets	1,753	284
Total current assets	52,765	12,854
Restricted cash	3,955	4,029
Property and equipment, net	2,310	2,329
Notes receivable from related parties		95
Other long term assets	53	36
Intangible assets, net	6,363	6,893
Goodwill	5,577	5,577
Total assets	71,023	31,813
Current liabilities
Accounts payable	1,129	1,804
Accrued liabilities	2,633	2,953
Deferred revenue	201	1,253
Line of credit obligation	3,813
Total current liabilities	7,776	6,010
Deferred tax liability	3,281	3,481
Line of credit obligation		3,590
Other long-term liabilities	92	3
Total liabilities	11,149	13,084
Commitments and contingencies (Notes 8, 9 and 10)
Stockholders' equity (deficit)
Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2014
Common stock, par value $0.001, 200,000,000 and 12,514,224 shares authorized at December 31, 2014 and 2013, respectively, 20,405,066 and 1,541,781 shares issued and outstanding at December 31, 2014 and 2013, respectively	21	2
Additional paid-in capital	173,141
Accumulated deficit	-113,288	-94,453
Total stockholders' equity (deficit)	59,874	-94,451
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	71,023	31,813
Redeemable Convertible Series A- 2 Preferred Stock [Member]
Current liabilities
Redeemable convertible preferred stock		49,200
Stockholders' equity (deficit)
Total stockholders' equity (deficit)		49,200
Redeemable Convertible Series A- 1 Preferred Stock [Member]
Current liabilities
Redeemable convertible preferred stock		63,980
Stockholders' equity (deficit)
Total stockholders' equity (deficit)		$63,980

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10,000,000
Common stock, par value	$0.00	$0.00
Common stock, authorized	200,000,000	12,514,224
Common stock, shares issued	20,405,066	1,541,781
Common stock, outstanding	20,405,066	1,541,781
Redeemable Convertible Series A- 2 Preferred Stock [Member]
Redeemable convertible preferred stock, par value		$0.00
Redeemable convertible preferred stock, shares authorized		4,978,662
Redeemable convertible preferred stock, shares issued		3,556,186
Redeemable convertible preferred stock, shares outstanding		3,556,186
Redeemable Convertible Series A- 1 Preferred Stock [Member]
Redeemable convertible preferred stock, par value		$0.00
Redeemable convertible preferred stock, shares authorized		4,978,662
Redeemable convertible preferred stock, shares issued		4,978,661
Redeemable convertible preferred stock, shares outstanding		4,978,661

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenue	$10,644,000	$11,914,000	$11,294,000
Cost of revenue	7,233,000	6,423,000	7,253,000
Gross profit	3,411,000	5,491,000	4,041,000
Operating expense
Selling, general and administrative	9,003,000	6,698,000	6,876,000
Research and development	4,125,000	5,490,000	1,792,000
Total operating expense	13,128,000	12,188,000	8,668,000
Loss from operations	-9,717,000	-6,697,000	-4,627,000
Interest expense, net	-77,000	-36,000	-7,000
Net loss before income taxes	-9,794,000	-6,733,000	-4,634,000
Income tax benefit	0	2,671,000	2,041,000
Net loss	-9,794,000	-4,062,000	-2,593,000
Effective preferred stock dividends		-1,695,000	-1,589,000
Net loss attributable to common stockholders	($9,794,000)	($5,757,000)	($4,182,000)
Net loss per common share basic and diluted	($1.04)	($3.76)	($2.84)
Weighted-average common shares used to compute basic and diluted net loss per share	9,441	1,531	1,474

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)	Total	Redeemable Convertible Series A- 2 Preferred Stock [Member]	Redeemable Convertible Series A- 1 Preferred Stock [Member]	Preferred Stock Series A-2 [Member]	Preferred Stock Series A-1 [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Earnings (Deficit) [Member]
Beginning Balance at Dec. 31, 2011	$25,104,000			$4,000	$5,000	$1,000	$23,762,000	$1,332,000
Beginning Balance, Shares at Dec. 31, 2011				3,556,000	4,979,000	1,463,000
Exercise of stock options	5,000						5,000
Exercise of stock options, Shares	17,000					17,000
Vesting of common stock pursuant to restricted stock awards	80,000					1,000	79,000
Stock option expense	28,000						28,000
Reclassification from permanent to temporary equity and accretion of redemption value	-42,484,000	20,800,000	21,700,000	-4,000	-5,000		-23,874,000	-18,601,000
Reclassification from permanent to temporary equity and accretion of redemption value, shares		3,556,000	4,979,000	-3,556,000	-4,979,000
Net loss	-2,593,000							-2,593,000
Ending Balance at Dec. 31, 2012	-19,860,000	20,800,000	21,700,000			2,000		-19,862,000
Ending Balance, Shares at Dec. 31, 2012		3,556,000	4,979,000			1,480,000
Exercise of stock options	24,000						24,000
Exercise of stock options, Shares	62,000					62,000
Vesting of common stock pursuant to restricted stock awards	73,000						73,000
Stock option expense	52,000						52,000
Accretion of redemption value	-70,678,000	28,400,000	42,280,000				-149,000	-70,529,000
Beneficial dividend	0
Net loss	-4,062,000							-4,062,000
Ending Balance at Dec. 31, 2013	-94,451,000	49,200,000	63,980,000			2,000		-94,453,000
Ending Balance, Shares at Dec. 31, 2013		3,556,000	4,979,000			1,542,000
Exercise of stock options	56,000					1,000	55,000
Exercise of stock options, Shares	105,000					104,000
Stock option expense	404,000						404,000
Accretion of redemption value	-760,000	200,000	560,000				-93,000	-667,000
Preferred stock dividends paid in common shares, value						1,000	7,306,000	-7,307,000
Preferred stock dividends paid in common shares, shares						1,218,000
Conversion of preferred stock to common stock, value	113,940,000	-49,400,000	-64,540,000			9,000	113,931,000
Conversion of preferred stock to common stock, shares		-3,556,000	-4,979,000			8,635,000
Issuance of common stock, net of discount	52,614,000					9,000	52,605,000
Issuance of common stock, net of discount, shares						9,429,000
Repurchase of common stock, value	-131,000					-1,000	-130,000
Repurchase of common stock, shares						-423,000
Offering costs	-2,003,000						-2,003,000
Common stock forfeiture, value	-1,000						-1,000
Common stock forfeiture, shares						-100,000
Beneficial dividend							1,067,000	-1,067,000
Net loss	-9,794,000							-9,794,000
Ending Balance at Dec. 31, 2014	$59,874,000					$21,000	$173,141,000	($113,288,000)
Ending Balance, Shares at Dec. 31, 2014						20,405,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net loss	($9,794)	($4,062)	($2,593)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	465	462	437
Amortization of intangible assets	529	531	531
Deferred income taxes		-2,719	-1,654
Stock-based compensation expense	404	126	108
Losses and adjustments associated with assets held for sale		14	35
Changes in operating assets and liabilities
Accounts and unbilled receivables	1,877	-758	1,198
Inventories	3	728	-708
Other current assets	-1,469	512	-556
Notes receivable from related parties	95
Other long term assets	-17	-2	1
Accounts payable	-675	-209	429
Accrued liabilities	-365	1,766	-327
Deferred revenue	-1,051	-1,090	1,262
Income tax (receivable) payable	-4	100	-1,052
Net cash used in operating activities	-10,002	-4,601	-2,889
Cash flows from investing activities
Purchases of investments		-5,498	-2,000
Sales/maturities of investments	1,250	3,250
Acquisitions of property and equipment	-316	-119	-470
Proceeds from sales of equipment and assets held for sale		10	148
Net cash provided by (used in) investing activities	934	-2,357	-2,322
Cash flows from financing activities
Borrowings under line of credit agreement	223	2,450	1,140
Sales/maturities of investments in pledged accounts		3,000
Restricted cash	74	-2,528	-1,339
Net proceeds from issuance of common shares	50,614
Repurchase of common stock	-131
Proceeds from exercise of stock options	56	24	5
Net cash provided by (used in) financing activities	50,836	2,946	-194
Net increase (decrease) in cash and cash equivalents	41,768	-4,012	-5,405
Cash and cash equivalents
Beginning of period	3,954	7,966	13,371
End of period	45,722	3,954	7,966
Supplemental schedule of cash flow information
Cash paid for interest	91	46	13
Cash paid for taxes	25	45	628
Non-cash financing and investing transactions
Transfer of investments to pledged accounts		3,000
Conversion of preferred stock to common stock	113,940
Preferred stock dividends paid in common shares	7,307
Beneficial dividend	1,067
Reclass from permanent to temporary equity and accretion of preferred stock redemption value	760	70,679	42,500
Capital lease obligation	$130

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Business Activities and Organization

Pfenex Inc. (“Company” or “Pfenex”) was incorporated in the state of Delaware in 2009. Pfenex is a clinical-stage biotechnology company engaged in the development of difficult to manufacture and high-value proteins, initially focused on biosimilar therapeutics, or biosimilars. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Lucentis is marketed by Genentech, Inc., a wholly-owned member of the Roche Group and Novartis AG, for the treatment of patients with retinal diseases. The Company is currently conducting a Phase 1b/2a trial in patients with wet age-related macular degeneration, or wet AMD, and expects interim safety and tolerability data in the first quarter of 2015, and expects to commence a Phase 3 trial in 2016. The Company’s next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b), marketed by Bayer AG for the treatment of multiple sclerosis. Early in 2015, the Company plans to initiate a Phase 1 trial. The Company believes it is the most advanced in global development of these biosimilar product candidates. In addition to the Company’s two lead product candidates, its pipeline includes five other biosimilar candidates as well as vaccine, generic and next generation biologic candidates. The Company filed the Investigational New Drug (“IND”) for its recombinant anthrax vaccine at the end of 2014.

The Company’s revenue in the near term is primarily related to monetizing its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein product sales which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees.

Reverse Stock Split

On June 27, 2014, the Company effected a 2.812-for-1 reverse stock split of its common and preferred stock. All share and per share information has been retroactively adjusted to reflect this reverse stock split.

Initial Public Offering

In July 2014, the Company completed its initial public offering (“IPO”) in which 8,333,333 shares of common stock at a price of $6.00 per share were issued and sold. Additionally, the Company sold 1,095,751 shares of common stock pursuant to the underwriters’ option to purchase additional shares. The Company received aggregate proceeds of approximately $52.6 million from the sale of shares of common stock, net of underwriters’ discounts and commissions, but before deducting paid and unpaid offering expenses of approximately $2.0 million. In connection with the IPO, (i) all shares of the Company’s outstanding convertible preferred stock automatically converted into 8,634,857 shares of common stock, (ii) the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends through July 28, 2014; (iii) the Company repurchased 423,185 shares of its common stock at a purchase price of $0.31 per share pursuant to the amended and restated subscription agreement, dated May 2, 2014, entered into with certain stockholders, including Signet Healthcare Partners Accredited Partnership III, LP and Signet Healthcare Partners QP Partnership III, LP; and (iv) certain members of the Company’s executive management team forfeited an aggregate of 100,000 shares of common stock.

Subsidiary—Pfenex Limited

In December 2013, to assist with its strategy of approaching the regulatory authorities in the EU for its pipeline products, the Company formed a new entity in the UK. An application for incorporation with the Registrar of Companies for England and Wales was filed and approved for the Company’s subsidiary, Pfenex Limited. There has been no activity in the subsidiary and therefore no intercompany relationship requiring elimination in the consolidated financial statements.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These adjustments consist of normal and recurring accruals, as well as non-recurring charges.

Segments

The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained at the Company’s facility in the United States.

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.

Short-Term Investments

The Company held investments in Certificates of Deposit with initial maturities exceeding three months. These financial instruments are carried at fair value, and interest earned on investments is included in interest income on the accompanying consolidated statements of operation.

Restricted Cash

In May 2012, the Company entered into a revolving line of credit agreement with Wells Fargo Bank, National Association (“Wells Fargo”) under which the Company may borrow up to $1.5 million. Additionally, the Company entered into a second line of credit with Wells Fargo in June 2013 under which the Company may borrow up to $2.4 million. The two lines of credit are secured by a security interest of first priority in favor of Wells Fargo in all funds deposited in two of the Company’s money market accounts held at Wells Fargo. Restrictions on the money market accounts will be removed when the lines of credit are paid in full and have expired. The lines of credit are due and payable in full in April 2015.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at two major financial institutions as of December 31, 2014 and 2013. For the Company’s cash position of $49.7 million as of December 31, 2014, which includes restricted cash of $4.0 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance.

Additional credit risk is related to the Company’s concentration of receivables. As of December 31, 2014, receivables were concentrated among two customers representing 95% of total net receivables and three customers as of December 31, 2013, representing 83%. For the years ended December 31, 2014, 2013 and 2012, revenue was concentrated among three customers representing 82%, 68% and 77% of total revenues, respectively. There were no supplier concentrations.

A portion of revenue is earned from sales outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s net revenue from U.S. and non-U.S. sources for the years ended December 31, 2014, 2013 and 2012 is as follows:

Years Ended December 31,

2014

2013

2012

(in thousands)

US Revenue

8,782

8,435

10,298

Non-US Revenue

1,862

3,479

996

10,644

11,914

11,294

During the year ended December 31, 2014, revenue earned from non-recurring sales in Germany accounted for approximately 10% of the Company’s revenue. During the year ended December 31, 2013, revenue earned from non-recurring sales in The Netherlands accounted for approximately 15% of the Company’s revenue. During 2012, no single foreign country accounted for more than 10% of the Company’s revenue.

Risk and Uncertainties

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of the Company’s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals.

Products developed by the Company require clearances from international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company.

The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.

Accounts and Unbilled Receivables

Accounts receivable represent primarily commercial receivables associated with the Company’s service fees, license fees, product sales and receivables from U.S. government contracts. Accounts receivable amounted to $1.9 million and $2.0 million as of December 31, 2014 and 2013, respectively. Unbilled receivables represent reimbursable costs in excess of billings and, where applicable, accrued profit related to long-term government contracts for which revenue has been recognized, but the customer has not yet been billed. Unbilled receivables amounted to $0.3 million and $1.5 million as of December 31, 2014 and 2013, respectively.

The Company evaluates the collectability of its receivables based on a variety of factors, including the length of time the receivables are past due, the financial health of its customers and historical experience. Based upon the review of these factors, the Company recorded an allowance for doubtful accounts of $0.6 million and $44 thousand at December 31, 2014 and 2013, respectively.

Fair Value of Financial Instruments

Financial instruments, including cash, cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, accrued liabilities and the lines of credit, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments. Other short-term investments are carried at fair value.

Inventories

Inventories consist of finished goods and are valued at the lower of cost or market. The Company regularly reviews inventories on hand to identify any inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements. No write-downs were recorded during the years ended December 31, 2014 or 2013.

Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from five to ten years with the exception of leasehold improvements which are amortized over the shorter of the lease term or their estimated useful life.

Intangible Assets

Intangible assets include customer relationships, developed technology and trade names related to the Company’s asset acquisition. Intangible assets have been capitalized and amortized over the estimated useful life of 15 years, 20 years and 15 years, respectively.

Impairment of Long-Lived Assets Other Than Goodwill

The Company assesses potential impairments to its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flow expected to result from the use of the assets. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset. No impairment was noted during the years ended December 31, 2014 and 2013.

Goodwill

Goodwill is the excess of purchase price over the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed, in a business combination. The Company does not amortize goodwill. Instead, goodwill is tested for impairment annually and between annual tests if the Company becomes aware of an event or a change in circumstances that would indicate the carrying amount may be impaired. The Company performs its annual impairment testing on December 31st of each year. The Company will first assess qualitative factors to determine whether the existence of events or circumstances suggests that it is more likely than not that goodwill is impaired. Unless it is more likely than not that goodwill is impaired, the Company does not perform the two-step impairment test. The Company’s determination as to whether, and, if so, the extent to which, goodwill becomes impaired is highly judgmental and based on assumptions regarding its projected future operating results, changes in the manner of its use of the acquired assets or its overall business strategy and regulatory, market and economic environment and trends. No impairment was noted during the years ended December 31, 2014 and 2013.

Revenue

The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein products which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving milestones and for product royalties. The specifics of the Company’s significant agreements are detailed in Note 11—Significant Research and Development Agreements.

The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement.

Upfront, nonrefundable payments that do not have stand-alone value are recorded as deferred revenue and recognized as revenue over the estimated period of performance. Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.

Revenue under service agreements are recorded as services are performed. These agreements do not require scientific achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement.

The Company recognizes revenue for its cost plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under the Company’s government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred.

The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. Where separate milestone payments do not meet these criteria, the Company recognizes revenue using a contingency-adjusted performance model over the period of performance. For the years ended December 31, 2014, 2013 and 2012, no revenue in connection with the achievement of milestones has been recognized.

The Company’s reagent protein products are comprised of internally developed reagent protein products and those purchased from original manufacturers for resale. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the Company’s price to the buyer is fixed or determinable, and (4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the Company, or the buyer is obligated to pay the Company and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. Reagent product revenue amounted to $1.2 million, $3.3 million and $0.7 million for the years ended December 31, 2014, 2013 and 2012, respectively. As of December 31, 2014, the Company has had minimal product returns related to reagent protein product sales. However, given the nature of the products, the Company has deemed it prudent to reserve $10 thousand, $18 thousand and $16 thousand for warranty and return rights as of December 31, 2014, 2013 and 2012, respectively. The reserve is a component of accounts and unbilled receivables, net in the accompanying consolidated balance sheets.

Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent.

Cost of Revenue

Cost of revenue includes costs incurred in connection with the execution of service contracts, as well as costs to manufacture or purchase, package and ship the Company’s reagent products.

Advertising

The Company expenses the cost of advertising when the advertising takes place. For each of the years ended December 31, 2013 and 2012, advertising expense was $0.3 million. There were no advertising expenditures in 2014.

Preclinical and Clinical Trial Accruals

The Company’s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on the Company’s behalf.

The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of series or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related series are recorded as prepaid expenses until the services are rendered.

Research and Development Expenses

Research and development expenses are recognized as incurred and amounted to $4.1 million, $5.5 million and $1.8 million for the years ending December 31, 2014, 2013 and 2012, respectively.

Stock-Based Compensation

Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of estimated forfeitures, over the requisite service period. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award.

The Company estimates the fair value of stock options and other equity-based compensation using a Black-Scholes option pricing model on the date of grant. The Black-Scholes valuation model requires multiple subjective inputs, which are discussed further in Note 12—Stock-Based Compensation. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally four years; however, certain provisions in the Company’s equity compensation plan provides for shorter and longer vesting periods under certain circumstances.

Comprehensive Loss

Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.

Income Taxes

The Company files U.S. federal income tax returns and California, Massachusetts and Missouri state tax returns. To date, the Company not been audited by the Internal Revenue Service or any state income tax authority; however all tax years from and including 2009 remain open for examination by federal and state tax authorities. The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. A deferred income tax asset or liability is computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future tax benefit, if any, to be derived from tax credits and loss carryforwards. Deferred income tax expense or benefit would represent the net change during the year in the deferred income tax asset or liability. Deferred tax assets, if any, are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Net Loss per Share of Common Stock

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, convertible notes payable, stock options and redeemable convertible preferred stock warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December 31, 2014, 2013 and 2012, diluted net loss per common share is the same as basic net loss per common share for those periods. For years ending December 31, 2013 and 2012, the Company had total accumulated dividends related to preferred stock in the amounts of $6.3 million and $4.6 million, respectively, which increased the net loss on a per share basis. There were no accumulated dividends related to preferred stock at December 31, 2014. Immediately prior to the IPO, the Company issued shares of common stock in connection with the payment of all accrued and unpaid dividends on the preferred stock upon the conversion of the convertible preferred stock to common stock. See Note 9—Common Stock and Preferred Stock.

Recently Issued Accounting Pronouncements

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to avail itself of this extended transition period and, as a result, it will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies.

In July 2013, the FASB issued guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. The adoption of this guidance did not have a material impact on the consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The effective date will be the first quarter of fiscal year 2018 using one of two retrospective application methods. The Company is currently evaluating the impact of the adoption of this accounting standard update on its financial statements.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. Fair Value Measurements
	Authoritative guidance defines fair value, establishes a framework for measuring fair value in U.S. GAAP and requires disclosures about fair value measurements.
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:

		•		Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at December 31, 2014 and December 31, 2013 included the Company’s cash, cash equivalents and investments in certificates of deposit. There were no Level 1 liabilities;

		•		Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at December 31, 2014 or December 31, 2013; and

		•		Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at December 31, 2014 or December 31, 2013.

	The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of December 31, 2014 and 2013, were determined using the inputs described above and are as follows:


						Fair Value Measurements at Reporting
						Data Using
			Total			Quoted Prices			Significant		Significant
						in Active			Other		Unobservable
						Markets for			Observable		Inputs
						Identical Assets			Inputs		(Level 3)
						(Level 1)			(Level 2)
			(in thousands)
	December 31, 2014
	Classified as current assets:
	Cash and money market funds		$	49,677		$	49,677		$	—	$	—
	Certificates of deposit			—			—			—		—

	Total			49,677			49,677			—		—
	Less cash, cash equivalents and restricted cash			(49,677	)		(49,677	)		—		—

	Total investments		$	—		$	—		$	—	$	—

	December 31, 2013
	Classified as current assets:
	Cash and money market funds		$	7,983		$	7,983		$	—	$	—
	Certificates of deposit			1,250			1,250			—		—

	Total			9,233			9,233			—		—
	Less cash, cash equivalents and restricted cash			(7,983	)		(7,983	)		—		—

	Total investments		$	1,250		$	1,250		$	—	$	—

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment
	Property and equipment consisted of the following:


		December 31,
		2014			2013
		(in thousands)
	Furniture and equipment	$	157		$	32
	Computers and IT equipment		190			86
	Purchased software		686			674
	Lab and research equipment		2,837			2,695
	Leasehold improvements		348			336
	Other fixed assets		35			35

	Total property and equipment, gross		4,253			3,858
	Less: accumulated depreciation and amortization		(1,943	)		(1,529	)

	Total property and equipment, net	$	2,310		$	2,329


	Total property and equipment assets under capital lease as of December 31, 2014 and 2013 were $0.2 million and $3 thousand, respectively. Accumulated depreciation related to assets under capital lease as of these dates were $3 thousand and $2 thousand, respectively. For the years ended December 31, 2014, 2013 and 2012, total depreciation and amortization expense was $0.5 million, $0.5 million and $0.4 million, respectively, which is included in selling, general and administrative expenses and research and development in the accompanying consolidated statements of operations as follows:


		Years ended December 31,
		2014			2013			2012
		(in thousands)
	Selling, general and administrative	$	366		$	285		$	357
	Research and development		99			177			80

	Total depreciation and amortization expense	$	465		$	462		$	437

Notes_Receivable_from_Related_

Notes Receivable from Related Parties	12 Months Ended
Notes Receivable from Related Parties	Dec. 31, 2014
Related Party Transactions [Abstract]
Notes Receivable from Related Parties	4. Notes Receivable from Related Parties
	On January 21, 2010, the Company issued promissory notes (“Notes”) to certain officers and employees totaling $87 thousand in principal related to the payment of personal taxes associated with the restricted shares of common stock issued to these respective employees as discussed in Note 12—Stock-Based Compensation. The principal balance of the Notes were due together with accrued and unpaid interest on the earliest of: (i) January 21, 2015, (ii) upon the occurrence and during the continuance of an event of default under the Notes, (iii) the closing of a corporate event affecting the existing ownership structure, and (iv) the sale of any shares of common stock of the Company held by the maker to a third party. The Notes bore simple interest at 2.45% per annum. In June 2014, the Company’s Board of Directors (“board of directors”) approved the forgiveness of the principal amount and any accrued interest for each of the Notes and to gross up each affected employee’s compensation, in full, for any withholding tax obligations incurred in connection with such forgiveness. The total charge of $157 thousand for the write-off of the Notes, interest receivable, and related tax forgiveness was recorded in June 2014 and has been included in selling, general and administrative expenses in the accompanying consolidated statement of operations. The composition of notes receivable balance as of December 31, 2014 and 2013 was as follows:


		December 31,
		2014		2013
		(in thousands)
	Principal balance	$	—	$	87
	Accrued and unpaid interest		—		8

	Total notes receivable	$	—	$	95

Intangible_Assets

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. Intangible Assets
	Intangible assets consisted of the following:


		December 31,
		2014			2013
		(in thousands)
	Customer relationships	$	3,750		$	3,750
	Developed technology		4,400			4,400
	Trade names		910			910

	Gross intangible assets		9,060			9,060
	Less: Accumulated amortization		(2,697	)		(2,167	)

	Total intangible assets, net	$	6,363		$	6,893


	Amortization expense was $0.5 million for each of the years ended December 31, 2014, 2013 and 2012. Amortization expense is included within selling, general and administrative expense in the accompanying consolidated statements of operations. As of December 31, 2014, estimated amortization expense for the next five years amounts to approximately $0.5 million per year.

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
Accrued Liabilities	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Liabilities	6. Accrued Liabilities
	Accrued liabilities consisted of the following:


		December 31,
		2014		2013
		(in thousands)
	Accrued vacation	$	379	$	321
	Deferred rent		247		238
	Accrued bonuses		913		735
	Other accrued employee-related liabilities		125		36
	Accrued professional fees		221		191
	Accrued supplier liability		198		747
	Accrued subcontractor costs		292		526
	Other accrued liabilities		258		159

	Total accrued liabilities	$	2,633	$	2,953

Lines_of_Credit_Obligation

Lines of Credit Obligation	12 Months Ended
Lines of Credit Obligation	Dec. 31, 2014
Debt Disclosure [Abstract]
Lines of Credit Obligation	7. Lines of Credit Obligation
	The Company entered into two Revolving Line of Credit (“LOC”) agreements with Wells Fargo. The first LOC was entered into in May 2012 (“2012 LOC”) and the second in June 2013 (“2013 LOC”). The maximum capacity for the 2012 LOC and 2013 LOC is $1.5 million and $2.4 million, respectively, for a total capacity of $3.9 million. Both LOCs are collateralized by money market accounts held at Wells Fargo. The documents governing the credit facilities contain both financial and other covenants. The Company was not in compliance with covenants pertaining to (i) the delivery of its 2012 audit report, which was delivered before May 15, 2014 along with the Company’s 2013 audit report; (ii) the pre-approval for certain capital expenditures; and (iii) the pre-approval required for entering into a lease for a commercial copier/printer. On April 2, 2014, the Company obtained from Wells Fargo a waiver for the covenants and confirmation that the Company may repurchase common stock up to a maximum of $0.5 million. On June 24, 2014, the Company entered into an amendment to the credit facilities which allows the Company to (i) make additional investments in fixed assets in any fiscal year; (ii) incur operating lease expenses in any fiscal year up to $0.6 million; and (iii) declare or pay any dividend or distribution either in cash, stock or any other property, or redeem, retire, repurchase or otherwise acquire any shares of any class of stock in connection with the Company’s IPO. In January 2015, the Company entered into an amendment which increased the annual limit on operating lease expenses from $0.6 million to $0.9 million.
	As of December 31, 2014, the amount drawn down on the lines of credit was $1.4 million and $2.4 million for the 2012 LOC and the 2013 LOC, respectively, for a total outstanding amount of $3.8 million. Both lines of credit are due and payable in April 2015. As of December 31, 2014, the 2012 LOC was bearing a fixed interest rate of 2.00% above LIBOR, or 2.25%. As of December 31, 2014, the 2013 LOC was bearing fixed interest rates ranging from 2.25% to 2.375%. The Company recognized $85 thousand, $43 thousand and $14 thousand of interest expense related to the LOCs for the years ended December 31, 2014, 2013 and 2012, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies
	Lease Agreements
	In June 2010, the Company entered into a lease agreement (“Lease”) with a landlord for an initial term of 10 years, for its corporate headquarters comprised of one building located in San Diego, California. Occupation of the premises under the Lease began in April 2011. Under the terms of the Lease, the Company pays annual base rent, subject to an annual fixed percentage increase, plus its share of common operating expenses. The annual base rent was subject to abatement of 50% for the first year of the lease. The Company recognizes rent expense on a straight-line basis over the lease term.
	In September 2014, the Company amended its operating lease agreement to extend the term of the lease for an additional three years through March 31, 2024 and to lease additional facilities consisting of 7,315 square feet, resulting in a total increase in the estimated rent payments over the life of the lease by approximately $2.9 million. Base rent payments for the new space commenced in December 2014 and will increase total estimated rent payments over the life of the lease by approximately $1.5 million. The extended term on the existing space will increase total estimated rent payments by approximately $1.4 million. In addition to the base rent, the company is obligated to pay certain customary amounts for its share of operating expenses and tax obligations.
	Rent expense was $0.4 million for each of the years ended December 31, 2014, 2013 and 2012, which is included in selling, general and administrative and research and development expenses in the accompanying consolidated statements of operations as follows:


		Years Ended December 31,
		2014		2013		2012
		(in thousands)
	Selling, general and administrative	$	279	$	184	$	278
	Research and development		99		175		81

	Total rent expense	$	378	$	359	$	359

	In addition to the facilities lease, the Company has entered into operating and capital lease agreements for office and lab equipment that expire at various dates through December 2019.
	As of December 31, 2014, the total estimated future annual minimum lease payment obligations under the Company’s noncancelable leasing arrangements, including the facilities lease described above, are as follows:


		Payment Amounts
		Operating		Capital Leases		Total
		Leases		Capital Leases		Total
		(in thousands)
	2015	$	586	$	49	$	635
	2016		608		49		657
	2017		624		48		672
	2018		558		—		558
	2019		574		—		574
	Thereafter		2,628		—		2,628

	Total future minimum lease payments	$	5,578	$	146	$	5,724

	Indemnification
	In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. As of December 31, 2014, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.
	In accordance with the Company’s amended and restated Certificate of Incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. In addition, the Company has also entered into indemnification agreements with its directors, executive officers and certain other officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification and there are no claims that the Company is aware of that could have a material effect on the Company’s consolidated financial statements. There have been no claims to date and the Company has a director and officer insurance policy that may enable it to recover a portion of any amounts paid for future claims.
	Development and Service Contracts
	In connection with certain long-term contractual obligations, the Company is obligated to make payments of up to $2.6 million over the next twelve months.
	Contingencies
	From time to time, the Company may be involved in legal proceedings, claims, and litigation in the ordinary course of business. At December 31, 2014 and 2013 there were no pending legal proceedings.

Common_Stock_and_Preferred_Sto

Common Stock and Preferred Stock

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Common Stock and Preferred Stock

9. Common Stock and Preferred Stock

Prior to the completion of its IPO in July 2014, the Company was authorized to issue common stock and Series A-1 and Series A-2 redeemable convertible preferred stock. Immediately prior to the completion of the Company’s IPO, all of the outstanding shares of convertible preferred stock automatically converted into 8,634,857 shares of common stock. The Company issued 1,217,784 shares of common stock in connection with the payment of all accrued and unpaid dividends on the preferred stock upon the conversion of the convertible preferred stock to common stock immediately prior to the completion of the IPO. Members of the Company’s management team also forfeited an aggregate of 100,000 shares of common stock in connection with the completion of the IPO.

Common Stock

Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of other classes of stock outstanding.

Preferred Stock

Pursuant to the amended and restated certificate of incorporation filed by the Company immediately prior to the completion of its IPO, the board of directors is authorized to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in the Company’s control or other corporate action.

Series A-1 and A-2 Redeemable Convertible Preferred Stock

The Series A-1 and A-2 preferred stock had a contingent redemption feature allowing redemption by the holders at any time after December 31, 2014 upon the affirmative vote of sixty-six and two thirds (66 2⁄3%) of the holders. As the event that would trigger the redemption of the redeemable convertible preferred stock was not solely within the Company’s control, the redeemable convertible preferred stock had been classified as mezzanine equity (outside of permanent equity) on the Company’s consolidated balance sheets. The shares were to be redeemed by paying cash in an amount per share equal to the greater of (i) the Series A original issue price and any Series A dividends accrued but unpaid and (ii) the then-current fair market value of such shares.

The Company immediately recognized the changes in the redemption value as they occurred and the carrying value of the security was adjusted to equal what the redemption amount would be as if redemption were to occur at the end of the reporting date based on the conditions that exist as of that date. There was no limit to the maximum amount the Company could be required to pay. The value adjustments made to the redemption values at June 30, 2014 and December 31, 2013 were increases of $0.8 million and $71.0 million, respectively.

Series A-1 stock was subject to a cumulative dividend of four percent (4%) compounded quarterly, whether or not declared. Each share of Series A-1 stock was convertible into 0.91966 shares of common stock, subject to adjustments for certain dilutive events. Series A-2 stock was subject to a cumulative dividend of eight percent (8%) compounded quarterly, whether or not declared. Each share of Series A-2 stock was convertible into 1.1406 shares of common stock, subject to adjustments for certain dilutive events.

As of December 31, 2013, there had been no conversions of redeemable convertible preferred stock to common stock by either Series A-1 or Series A-2 stockholders, and there were no dilutive issuances of common stock.

As of December 31, 2013, no dividends had been declared or paid. Based on the IPO price of $6.00 per share and the offering closing on July 29, 2014, we issued 1.217,784 shares of common stock to holders of our outstanding preferred stock prior to the offering in satisfaction of these accrued dividends through July 28, 2014. Cumulative dividends as of July 28, 2014 and December 31, 2013 were as follows:

Cumulative as of July 28, 2014

Cumulative as of

December 31, 2013

Dividends

Dividends per

per Share

(in thousands except dividends per share)

Series A-2

4,457

1.25

3,815

1.07

Series A-1

2,850

0.57

2,470

0.5

7,307

6,285

In connection with the IPO, the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends on the preferred stock through July 28, 2014.

Commitment_to_Repurchase_Stock

Commitment to Repurchase Stock	12 Months Ended
Commitment to Repurchase Stock	Dec. 31, 2014
Equity [Abstract]
Commitment to Repurchase Stock	10. Commitment to Repurchase Stock
Commitment to Repurchase Stock	On December 1, 2009, the Company entered into a common stock subscription agreement with three investors (“Investors”) pursuant to which the Company agreed to repurchase a maximum of 423,185 shares of common stock at a price per share of $0.31. Pursuant to the amended and restated subscription agreement, dated May 2, 2014, the Company repurchased all 423,185 shares of common stock at $0.31 price per share immediately prior to the completion of the Company’s IPO in July 2014. The total cost of the repurchase was $131 thousand.

Significant_Research_and_Devel

Significant Research and Development Agreements	12 Months Ended
Significant Research and Development Agreements	Dec. 31, 2014
Research and Development [Abstract]
Significant Research and Development Agreements	11. Significant Research and Development Agreements
	The Company has two types of research and development agreements (i) those where it receives funding to advance its own products (“Funding Agreements”) and (ii) those where it assists customers in developing their products (“Collaboration Agreements”).
	Funding Agreements
	Stelis Biopharma Private Limited, a subsidiary of Strides Arcolab Limited
	In December 2012, the Company and Stelis Biopharma Private Limited (“Stelis”), entered into a Joint Development & License Agreement (“JDLA”) the purpose of which is to collaborate to develop certain therapeutic biosimilars through the completion of the first Phase 1 clinical trial. Under the terms of the agreement, Stelis is responsible for paying the costs associated with the Phase 1 trials and the manufacturing of the drug product for the trials. Stelis is obligated to reimburse the Company for any and all payments made to third party service providers for Phase 1 trials. As of December 31, 2012 the total of all reimbursable costs was $0.2 million. These reimbursable costs were paid in full to Pfenex in 2013. In February 2015, the Company notified Stelis that it was removing PF530 Interferon beta 1B, PF726 PEGylated interferon beta 1B and PF529 PEGylated filgrastim from the JDLA. In March 2013, the Company and Stelis entered into a joint venture agreement (“JVA”). The JVA was established to provide a vehicle for the advancement of biosimilars successful in Phase 1 trials under the JDLA. Under the terms of the JVA, both parties share equally in all decisions, and share revenue and costs 51% to Stelis and 49% to the Company. As of December 31, 2014, there was no investment in the joint venture by the Company, and there has been no activity in the joint venture (“JV”) to date. Once a biosimilar product successfully completes a Phase 1 trial and Stelis and the Company agree to contribute the biosimilar to the JV, the JV will incur activity.
	The U.S. Department of Health and Human Services
	In July 2010, the Company entered into a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services to develop a production strain and process for the production of bulk recombinant protective antigen (“rPA”) from anthrax. The arrangement is a cost plus fixed fee contract comprised of a base program and five (5) follow on options at BARDA’s election. At the inception of the contract, both BARDA and the Company entered into the arrangement with the expectation that BARDA would fund all costs of development and no costs in excess of the arrangement would be incurred by the Company. In December 2014, the Company filed the IND for Px563L, BARDA extended the contract and provided additional funding, increasing the total contract to $25.2 million.
	Revenue is recognized in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under this government contract primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under the BARDA contract, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under this BARDA contract, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable. The Company recorded revenues of $6.6 million, $4.2 million and $3.7 million for services performed in the years ended December 31, 2014, 2013 and 2012, respectively. Reimbursable costs related to fulfilling on this contract amounted to $5.0 million, $2.3 million and $2.5 million for the years ended December 31, 2014, 2013 and 2012, respectively, and are reflected in cost of revenue in the accompanying consolidated statements of operations. The billing of any overage in indirect cost rates over the approved provisional rates in the contract is not allowed. Any such overage is expensed as incurred. When and if final rates with Defense Contract Audit Agency are approved, the Company will recognize any change in revenue resulting from the rate change in the period such revised rates are approved and as such this would be considered a change in estimate. This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 whereupon BARDA may immediately terminate the agreement early for convenience, or request the Company to stop all or any part of the work for a period of at least 90 days. If BARDA is not adequately funded, there is a potential that some or all of the follow on options could be delayed or never elected.
	The National Institute of Allergy and Infectious Diseases
	In September 2012, the Company entered into a contract with the National Institute of Allergy and Infectious Diseases (“NIAID”) to provide services to advance vaccine components and technologies that accelerate the immune response for use in post-event settings following the intentional release of the NIAID Category A Priority Pathogen Bacillus anthracis or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A Priority Pathogen B. anthracis. The arrangement is a cost plus fixed fee contract comprised of a base program and thirteen (13) follow on options at NIAID’s election. At the inception of the contract, both NIAID and the Company entered into the arrangement with the expectation that NIAID would fund all costs of development and no costs in excess of the arrangement would be incurred by the Company. The total amount of the contract including options is $22.9 million, with $2.2 million eligible for payment during the base program of approximately 14 months. The fixed fee is paid as specific activities are completed. In December 2014, NIAID exercised the first option period, increasing the funding to $3.0 million. The contract has been extended through the end of 2015.
	Revenue is recognized in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under this government contract primarily include direct labor, subcontracts and indirect costs. In addition, the Company receives a fixed fee under the NIAID contract, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under this NIAID contract, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable. The Company recorded revenues of $1.0 million, $0.8 million and $0.1 million for services performed in the years ended December 31, 2014, 2013 and 2012, respectively. Reimbursable costs related to fulfilling this contract amounted to $0.5 million, $0.3 million and $3 thousand for the years ended December 31, 2014, 2013 and 2012, respectively, and are reflected in cost of revenues in the accompanying consolidated statements of operations. The billing of any overage in indirect cost rates over the approved provisional rates in the contract is not allowed. Such overage is expensed as incurred. When and if final rates with Defense Contract Audit Agency are approved, the Company will recognize any change in revenue resulting from the rate change in the period such revised rates are approved and as such this would be considered a change in estimate. This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 wherein NIAID may immediately terminate the agreement early for convenience, or request the Company to stop all or any part of the work for a period of at least 90 days. If NIAID is not adequately funded, there is a potential that some or all of the follow on options could be delayed or never elected.
	Leidos
	In 2009, the Company entered into a subcontract agreement with Leidos to evaluate the Malaria antigen using Pfenex Expression Technology™ and to provide production and support services in manufacturing the Malaria vaccine. The original contract was amended to increase scope of services resulting in a value of $8.4 million. The arrangement is a fixed fee contract for services to be performed over a five year contract term.
	Revenue is recognized as services are performed. The Company recognized $0.2 million, $2.1 million and $2.2 million in revenue for services performed in each of the years ended December 31, 2014, 2013 and 2012, respectively, as recorded in the accompanying consolidated statements of operations. The Company also recorded deferred revenues of $0.2 million as of December 31, 2013. No deferred revenues were recorded as of December 31, 2014. The scope of the agreement was completed in September of 2014 and the Company is no longer providing services under this agreement.

	Crucell
	In July 2012, the Company entered into a supply agreement with Crucell to supply Circumsporozoite Protein (“CSP”). The total order was valued at $1.8 million. The Company shipped the product to Crucell in 2013 at which time the revenue and related expenses were recognized.
	Collaboration Agreements
	Boehringer Ingelheim International GmbH
	Effective December 2010, the Company entered into a three (3) year transaction agreement with Boehringer Ingelheim International GmbH (“BII”) to provide BII with access to the Company’s proprietary technology to express BII and BII’s clients’ proteins. During the collaboration, BII had the option to obtain a commercial license for up to four (4) designated proteins. All collaborations and licenses under the agreement are nonexclusive. Under the terms of the agreement, BII paid the Company an annual technology fee of $0.2 million and guaranteed a minimum fee of $0.6 million. Additionally, for providing protein expression services, BII will pay the Company approximately $0.4 million per protein expression program with a guaranteed minimum of $1.05 million (“Service Guarantee”) during the term of the agreement. The Service Guarantee is reduced by approximately $0.4 million each time the Company refuses to enter into a service agreement for one of BII or BII’s clients’ requests to provide protein expression services for a specific express protein.
	The Company evaluated each of the deliverables included within the BII agreement and concluded the underlying deliverables met the criteria to be considered separate units of accounting; therefore, the annual technology maintenance fee is recognized in equal monthly installments over the related twelve annual month period, and revenue associated with the feasibility service fees is recognized as the services are performed.
	The Company recorded license revenue associated with the BII annual technology maintenance fee of approximately $0.2 million for each of the years ending December 31, 2013 and 2012. As a result of the expiration of the transaction agreement, no license revenue was recorded for the BII technology maintenance fee in 2014. In fiscal year 2014 and 2013, the Company recognized feasibility revenue of $1.0 million and $5 thousand for services performed. No feasibility services were provided to BII during fiscal year 2012; therefore, no related revenue was recognized. As of December 31, 2013, the Company recorded deferred revenue of $1.0 million for Service Guarantee services to be performed. No deferred revenues were recorded as of December 31, 2014. All performance obligations pursuant to the contract were completed during 2014.
	MedImmune, LLC
	Effective May 2011, the Company entered into a research collaboration and license agreement with MedImmune, LLC (“MedImmune”) to collaborate with MedImmune on the development of manufacturing strains for MedImmune’s proprietary protein strains. Pursuant to the collaboration, MedImmune has the option to obtain a commercial license for its designated proteins. All collaborations and licenses under the agreement are nonexclusive. Under the terms of the agreement, MedImmune agreed to pay the Company $3.0 million in technology access fees and $2.4 million in research service fees, subject to adjustment each year for additional research services requested by MedImmune. If MedImmune elects to pursue a commercial license for any of the developed manufacturing strains, commercial license fees, annual maintenance fees, milestone payments and royalties will be due to the Company. MedImmune was entitled to terminate the research term of the agreement upon 90 days prior written notice. Early termination required certain minimum payment amounts, depending on the date of the early termination. In February 2013, MedImmune notified the Company that they were terminating the contract early due to a lack of microbial based portfolio projects that could use the Pfēnex Expression Technology®. Due to the termination, the Company revised the estimate of total technology access fees that it would earn to $1.75 million.
	The Company evaluated each of the deliverables included within the MedImmune agreement and concluded the technology access fees did not meet the criteria to be considered a separate unit of accounting. Therefore, the Company recognized revenue associated with the technology access fee as the research services were performed.

	Technology access fees and service revenue recognized during the years ended December 31, 2013 and 2012 totaled $1.2 million and $2.8 million, respectively. No revenue was recognized in 2014. All performance obligations pursuant to the contract were completed during 2013.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	12. Stock-Based Compensation
	Stock Option Plan
	The Company’s board of directors adopted, and the Company’s stockholders approved, the Company’s 2009 Equity Incentive Plan (“2009 Plan”) in 2009. The 2009 Plan terminated in connection with the Company’s IPO in 2014 and, accordingly, no awards will be granted under the 2009 Plan following the IPO. However, the 2009 Plan will continue to govern outstanding awards granted thereunder. An aggregate of 1.1 million shares of common stock was reserved for issuance under the 2009 Plan. The 2009 Plan provided for the grant of incentive stock options and for the grant of nonstatutory stock options, restricted stock, restricted stock units, and stock appreciation rights to the Company’s employees, directors and consultants. As of December 31, 2014, awards covering 0.9 million shares of common stock were outstanding under the 2009 Plan.
	In July 2014, the board of directors adopted a 2014 Equity Incentive Plan (“2014 Plan”) and the Company’s stockholders approved it. The 2014 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to employees and any parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants and parent and subsidiary corporations’ employees and consultants. A total of 1,356,219 shares of common stock have been reserved for issuance pursuant to the 2014 Plan. In addition, the shares reserved for issuance under the 2014 Plan include shares returned to the 2009 Plan as the result of expiration or termination of awards (provided that the maximum number of shares that may be added to the 2014 Plan pursuant to such previously granted awards under the 2009 Plan is 961,755 shares). The number of shares available for issuance under the 2014 Plan also includes an annual increase on the first day of each fiscal year beginning in 2015 and ending with and including the 2018 fiscal year, equal to the least of: (i) 1,356,219 shares; (ii) 2.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the board of directors may determine.
	Stock options granted to date under the 2009 Plan and the 2014 Plan have a term of ten years from the date of grant, and generally vest over a four-year period. However, in the event that an incentive stock option (“ISO”) granted to a participant who, at the time the ISO is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, the term of the ISO shall be five (5) years from the grant date or such shorter term as may be provided in the award agreement. In July 2014, the board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”) and the stockholders approved it. A total of 355,618 shares of common stock have been reserved for sale under the ESPP. In addition, the ESPP provides for annual increases in the number of shares available for sale under the ESPP on the first day of each fiscal year beginning in 2015, equal to the least of: (i) 355,618 shares; (ii) 1.5% of the outstanding shares of the common stock on the last day of the immediately preceding fiscal year; or (iii) such other amount as may be determined by the administrator. No shares have been purchased under the ESPP as of December 31, 2014.
	Stock Options
	Total stock-based compensation expense associated with stock options granted was $0.4 million, $52 thousand and $28 thousand for the years ending December 31, 2014, 2013 and 2012, respectively.
	The exercise price of all options granted during the years ended December 31, 2014, 2013 and 2012 was equal to the estimated fair value of the underlying common stock on the date of grant. The fair value of each stock option granted is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair values of the stock option, including the effect of estimated forfeitures, are then expensed over the requisite service period which is generally the vesting period. The following assumptions were used to estimate the fair value of stock options:


		Years Ended December 31,
		2014		2013				2012
	Risk-free interest rate	1.7 – 2.0%			1.2	%			1	%
	Expected volatility	48.7 – 55.0%			54.4	%			47.1	%
	Expected dividend yield	0.00%			0	%			0	%
	Expected life of options in years	5.3-6.1			6.1				6
	The fair value of equity instruments that are ultimately expected to vest, net of estimated forfeitures, are recognized and amortized on a straight-line basis over the requisite service period. The Black-Scholes option-pricing model requires multiple subjective inputs, including a measure of expected future volatility. Prior to the Company’s IPO, the Company’s stock did not have a readily available market. Consequently, the expected future volatility was based on the historical volatility for comparable publically traded companies over the most recent period commensurate with the estimated expected term of the Company’s stock options. Following the completion of the Company’s IPO in July 2014, the fair value of options granted is based on the closing price of the Company’s common stock on the date of grant as quoted on the NYSE MKT.
	The risk-free interest rate assumption is based upon observed interest rates during the period appropriate for the expected term of the options. The expected term of options granted represents the period of time the options are expected to be outstanding. With the exception of 1,217,784 shares of common stock issued in connection with the payment of all accrued and unpaid dividends on the preferred stock immediately prior to the completion of the Company’s IPO, the Company had never declared or paid dividends and has no plans to do so in the foreseeable future. Accordingly, the dividend yield assumption is based on the expectation that the Company will not pay dividends on its common stock in the future. Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The weighted-average grant date fair value of options granted during the year ended December 31, 2014, 2013 and 2012 was $4.60, $1.04 and $0.67, respectively. Total fair value of shares vested during the years ended December 31, 2014, 2013 and 2012 was $137 thousand, $57 thousand and $28 thousand, respectively.

	Stock option transactions under the Plan during the years ended December 31, 2014, 2013 and 2012 are as follows:


		Number of				Weighted				Weighted		Aggregate
		Options				Average				Average		Intrinsic Value
		(in thousands)				Exercise Price				Remaining		(in thousands)
										Contractual
										Term (in years)
	Outstanding at January 1, 2012		705			$	0.33
	Granted		139				1.49
	Exercised		(17	)			0.31
	Cancelled (forfeited)		(17	)			0.31

	Outstanding at December 31, 2012		810				0.53
	Granted		36				1.5
	Exercised		(62	)			0.39
	Cancelled (forfeited)		(26	)			0.89

	Outstanding at December 31, 2013		758				0.57
	Granted		611				8.89
	Exercised		(105	)			0.53
	Cancelled (forfeited)		(32	)			1.49

	Outstanding at December 31, 2014		1,232			$	4.68				7.63	$	4,301

	Vested and expected to vest at December 31, 2014		1,139			$	4.39				7.48	$	4,225
	Vested and exercisable at December 31, 2014		588			$	0.78				5.55	$	3,840
	The Company received $55 thousand, $24 thousand and $5 thousand for the years ended December 31, 2014, 2013 and 2012, respectively, for options exercised. Options outstanding at December 31, 2014 have a weighted average remaining contractual term of 7.6 years.
	As of December 31, 2014, there was approximately $2.1 million of unrecognized compensation cost related to unvested stock option awards, and the weighted average period over which this cost is expected to be recognized is 3.4 years.
	The total aggregate intrinsic value, which is the amount, if any, by which the exercise price was exceeded by the estimated fair value of the Company’s common stock, of options exercised, was $0.8 million, $89 thousand and $21 thousand for the years ended December 31, 2014, 2013 and 2012, respectively.
	In June 2014, the Company granted a total of 259,224 common stock options to purchase shares of the Company’s stock at an exercise price of $11.59 per share pursuant to the Plan. All of these options vest over four years.
	Restricted Stock Awards
	In January 2010, the Company granted 1,034,850 shares of restricted stock to certain officers and employees with an estimated value of $0.31 per share, or $0.3 million. No restricted stock was granted during 2014, 2013 or 2012. Compensation expense is recognized for grants of restricted stock awards using the estimated value of the Company’s stock on the date of grant. Stock compensation is recognized on a straight line basis over the vesting period, which is generally four years. The stock-based compensation expense related to these restricted stock awards amounted to $74 thousand and $80 thousand for the years ended December 31, 2013 and 2012, respectively. As all 1,034,850 shares were fully vested by December 31, 2013, there was no related compensation expense for the year ended December 31, 2014.

Retirement_Plan

Retirement Plan	12 Months Ended
Retirement Plan	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Retirement Plan	13. Retirement Plan
Retirement Plan	The Company has a 401K Savings Plan (“401K”). The 401K is for the benefit of all qualifying employees and permits voluntary contributions by employees up to a maximum percentage allowable by current IRS regulations. The Company does not provide matching of employee contributions.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes
	The components of the income tax benefit are as follows:


		Years Ended December 31,
		2014			2013			2012
		(in thousands)
	Income tax benefit
	Current	$	1,047		$	1,469		$	3,695
	Deferred		(1,047	)		1,202			(1,654	)

	Total benefit	$	—		$	2,671		$	2,041

	During the year ended December 31, 2014, no tax benefit or expense was recorded by the Company. During the years ended December 31, 2013 and 2012, the Company recorded an income tax benefit of $2.7 million and $2.0 million, respectively, which is principally attributable to U.S. federal and state income taxes. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s consolidated balance sheets at December 31, 2014 and 2013. The Company is subject to taxation in the United States and various state jurisdictions. The Company’s tax years for 2009 and forward are subject to examination by the United States and various state tax authorities. As of December 31, 2014, the Company had federal and state research and development credits carryforwards of approximately $467,000 and $328,000, respectively, to offset potential tax liabilities. The Company had federal and state net operating loss carryforwards of approximately $14.2 million and $15.8 million, respectively, as of December 31, 2014. The federal losses can be carried forward until 2032 and state losses until 2029 unless utilized.
	Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards.

	Significant components of the Company’s deferred tax assets as of December 31, 2014 and 2013 are shown below. A valuation allowance of $4.4 million and $0.4 million as of December 31, 2014 and 2013, respectively, has been established to offset deferred tax assets, as realization of such assets is uncertain.


		December 31,
		2014			2013
		(in thousands)
	Deferred tax assets
	Net operating losses	$	5,731		$	2,434
	Deferred revenue		80			180
	Other		1,837			1,241

	Total deferred tax assets		7,648			3,855

	Deferred tax liabilities
	Depreciation and amortization		(731	)		(772	)
	Intangible assets		(2,550	)		(2,709	)

	Total deferred tax liabilities		(3,281	)		(3,481	)

	Valuation allowance		(4,367	)		(374	)

	Net deferred tax liability	$	—		$	—

	The provision for income taxes differs from the U.S. federal statutory tax rate primarily due to state and local income taxes, valuation allowance established, and research and development credits.
	A reconciliation of the Company’s effective tax rate and federal statutory tax rate at December 31, 2014, 2013 and 2012 is as follows:


		December 31,
		2014						2013					2012
		(in thousands)
	Federal income taxes	$	(3,330	)		34	%	$	2,278		34.00	%	$	1,579		34.00	%
	State income taxes		(567	)		5.78	%		390		5.81	%		270		5.81	%
	Permanent items		126			(1.29	)%		(29	)	(0.43	)%		(24	)	(0.52	)%
	Valuation Allowance		3,994			(40.75	)%		(374	)	(5.58	)%		—		—	%
	Other		(223	)		2.26	%		406		6.06	%		216		4.66	%

	Total income tax benefit	$	—			0	%	$	2,671		39.86	%	$	2,041		43.95	%

	In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company did not have any uncertain income tax positions as of December 31, 2014.
	It is the Company’s practice to recognize interest and/or penalties related to income tax matters in income tax expense. Because the Company has no uncertain tax positions, it did not have any accrued interest or penalties included in its consolidated balance sheets at December 31, 2014 or 2013, and did not recognize any interest and/or penalties in its consolidated statements of operations and comprehensive income or loss during the years ended December 31, 2014, 2013 or 2012.
	The Company is subject to income tax in the United States and various states. The Company currently has no years under examination by any jurisdiction; however, the Company is subject to income tax examination by federal and various state tax authorities for the years beginning in 2009 due to federal and state statutes.

Net_Loss_Per_Share_of_Common_S

Net Loss Per Share of Common Stock	12 Months Ended
Net Loss Per Share of Common Stock	Dec. 31, 2014
Earnings Per Share [Abstract]
Net Loss Per Share of Common Stock	15. Net Loss Per Share of Common Stock
	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:


		December 31,
		2014			2013			2012
		(in thousands, except per share data)
	Net loss	$	(9,794	)	$	(4,062	)	$	(2,593	)
	Effective preferred stock dividend		—			(1,695	)		(1,589	)

	Net loss plus preferred stock dividend—basic and diluted	$	(9,794	)	$	(5,757	)	$	(4,182	)

	Weighted average shares used to compute basic and diluted net loss per share		9,441			1,531			1,474

	Basic and diluted net loss per common share	$	(1.04	)	$	(3.76	)	$	(2.84	)

	Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as-if converted method, for convertible securities, if inclusion of these is dilutive. Because the Company has reported a net loss for the years ended December 31, 2014, 2013 and 2012, diluted net loss per common share is the same as basic net loss per common share for those periods.
	The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding:


		December 31,
		2014			2013
	Redeemable convertible preferred stock		—			8,634,847
	Options to purchase common stock		1,231,886			757,805

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events
Subsequent Events	In February, 2015, the Company announced that it entered into an agreement with Hospira, Inc. (“Hospira”) to develop and commercialize PF582. Under the terms of the collaboration, the Company will receive a non-refundable upfront payment of $51 million once the collaboration receives antitrust approval, and, over the next five years and beyond, will be eligible to receive a combination of development and sales-based milestone payments up to an additional $291 million, and double-digit escalation royalties on net sales of the product. Hospira and the Company will share the Phase 3 equivalence clinical trial costs, and Hospira will be responsible for manufacturing and commercializing the product worldwide.

Quarterly_Financial_Data

Quarterly Financial Data	12 Months Ended
Quarterly Financial Data	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	17. Quarterly Financial Data (unaudited)
	The following is a summary of the quarterly results of the Company for the years ended December 31, 2014 and 2013 (unaudited):


			First			Second			Third			Fourth			Year Ended
			Quarter			Quarter			Quarter			Quarter			December 31
			(in thousands, except for per share data)
	2014
	Revenues		$	2,558		$	3,266		$	2,801		$	2,019		$	10,644
	Cost of revenues			1,908			2,544			1,579			1,202			7,233

	Gross profit			650			722			1,222			817			3,411
	Operating expenses			2,173			2,884			3,698			4,373			13,128
	Interest expense, net			18			21			19			19			77
	Income tax expense (benefit)			1			—			—			(1	)		—

	Net loss			(1,542	)		(2,183	)		(2,495	)		(3,574	)		(9,794	)

	Effective preferred stock dividends(1)			(435	)		(447	)		—			—

	Net loss attributable to common stockholders			(1,977	)		(2,630	)		(2,495	)		(3,574	)		(9,794	)

	Net loss per share:
	Basic and Diluted		$	(1.28	)	$	(1.67	)	$	(0.16	)	$	(0.18	)	$	(1.04	)
	Shares used in the calculation of net loss per share:
	Basic and Diluted			1,548			1,571			15,319			20,388			9,441
	2013
	Revenues		$	3,385		$	2,309		$	1,989		$	4,231		$	11,914
	Cost of revenues			2,029			1,306			1,153			1,935			6,423

	Gross profit			1,356			1,003			836			2,296			5,491
	Operating expenses			2,563			2,948			3,635			3,042			12,188
	Interest expense, net			1			9			7			19			36
	Income tax benefit			(482	)		(777	)		(1,116	)		(296	)		(2,671	)

	Net loss			(726	)		(1,177	)		(1,690	)		(469	)		(4,062	)

	Effective preferred stock dividends(1)			(408	)		(419	)		(430	)		(438	)		(1,695	)

	Net loss attributable to common stockholders			(1,134	)		(1,596	)		(2,120	)		(907	)		(5,757	)

	Net loss per share:
	Basic and Diluted		$	0.76		$	(1.04	)	$	(2.08	)	$	(0.59	)	$	(3.76	)
	Shares used in the calculation of net loss per share:
	Basic and Diluted			1,497			1,542			1,019			1,542			1,531

	-1	The holders of our convertible preferred stock were entitled to cumulative dividends prior and in preference to our common stock. Because the holders of our convertible preferred stock were entitled to participate in dividends, net loss attributable to common stockholders was equal to net loss adjusted for convertible preferred stock dividends for the period. Immediately upon the closing of our IPO, all outstanding shares of our redeemable convertible preferred stock, or our convertible preferred stock, were automatically converted into an aggregate of 8,634,847 shares of common stock and these holders were issued 1,217,784 shares of common stock for the payment of all accrued and unpaid dividends through July 28, 2014 in connection with such conversion based on the initial public offering price of $6.00 per share and the offering closing on July 29, 2014. See Note 15 to our financial statements for a description of the method used to compute basic and diluted net loss per share attributable to common stockholders and for a description of convertible preferred stock, respectively. Please refer to Note 9 of our consolidated financial statements for an explanation of the cumulative preferred stock dividends.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
Schedule II - Valuation and Qualifying Accounts	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS


		Years Ended December 31,
		2014			2013			2012
		(in thousands)
	Allowance for Doubtful Accounts:
	Beginning balance	$	44		$	16		$	0
	Charged to costs and expenses		559			44			16
	Reductions and write-offs		(18	)		(16	)		0

	Ending balance	$	585		$	44		$	16

	All other schedules have been omitted because they are not required, not applicable, or the required information is otherwise included.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Business Activities and Organization	Business Activities and Organization
	Pfenex Inc. (“Company” or “Pfenex”) was incorporated in the state of Delaware in 2009. Pfenex is a clinical-stage biotechnology company engaged in the development of difficult to manufacture and high-value proteins, initially focused on biosimilar therapeutics, or biosimilars. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Lucentis is marketed by Genentech, Inc., a wholly-owned member of the Roche Group and Novartis AG, for the treatment of patients with retinal diseases. The Company is currently conducting a Phase 1b/2a trial in patients with wet age-related macular degeneration, or wet AMD, and expects interim safety and tolerability data in the first quarter of 2015, and expects to commence a Phase 3 trial in 2016. The Company’s next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b), marketed by Bayer AG for the treatment of multiple sclerosis. Early in 2015, the Company plans to initiate a Phase 1 trial. The Company believes it is the most advanced in global development of these biosimilar product candidates. In addition to the Company’s two lead product candidates, its pipeline includes five other biosimilar candidates as well as vaccine, generic and next generation biologic candidates. The Company filed the Investigational New Drug (“IND”) for its recombinant anthrax vaccine at the end of 2014.
	The Company’s revenue in the near term is primarily related to monetizing its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein product sales which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees.
Reverse Stock Split	Reverse Stock Split
	On June 27, 2014, the Company effected a 2.812-for-1 reverse stock split of its common and preferred stock. All share and per share information has been retroactively adjusted to reflect this reverse stock split.
Initial Public Offering	Initial Public Offering
	In July 2014, the Company completed its initial public offering (“IPO”) in which 8,333,333 shares of common stock at a price of $6.00 per share were issued and sold. Additionally, the Company sold 1,095,751 shares of common stock pursuant to the underwriters’ option to purchase additional shares. The Company received aggregate proceeds of approximately $52.6 million from the sale of shares of common stock, net of underwriters’ discounts and commissions, but before deducting paid and unpaid offering expenses of approximately $2.0 million. In connection with the IPO, (i) all shares of the Company’s outstanding convertible preferred stock automatically converted into 8,634,857 shares of common stock, (ii) the Company issued 1,217,784 shares of common stock as payment of all accrued and unpaid dividends through July 28, 2014; (iii) the Company repurchased 423,185 shares of its common stock at a purchase price of $0.31 per share pursuant to the amended and restated subscription agreement, dated May 2, 2014, entered into with certain stockholders, including Signet Healthcare Partners Accredited Partnership III, LP and Signet Healthcare Partners QP Partnership III, LP; and (iv) certain members of the Company’s executive management team forfeited an aggregate of 100,000 shares of common stock.
Subsidiary - Pfenex Limited	Subsidiary—Pfenex Limited
	In December 2013, to assist with its strategy of approaching the regulatory authorities in the EU for its pipeline products, the Company formed a new entity in the UK. An application for incorporation with the Registrar of Companies for England and Wales was filed and approved for the Company’s subsidiary, Pfenex Limited. There has been no activity in the subsidiary and therefore no intercompany relationship requiring elimination in the consolidated financial statements.
Basis of Presentation	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These adjustments consist of normal and recurring accruals, as well as non-recurring charges.
Segments	Segments
	The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained at the Company’s facility in the United States.
Use of Estimates	Use of Estimates
	The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.
Short-Term Investments	Short-Term Investments
	The Company held investments in Certificates of Deposit with initial maturities exceeding three months. These financial instruments are carried at fair value, and interest earned on investments is included in interest income on the accompanying consolidated statements of operation.
Restricted Cash	Restricted Cash
	In May 2012, the Company entered into a revolving line of credit agreement with Wells Fargo Bank, National Association (“Wells Fargo”) under which the Company may borrow up to $1.5 million. Additionally, the Company entered into a second line of credit with Wells Fargo in June 2013 under which the Company may borrow up to $2.4 million. The two lines of credit are secured by a security interest of first priority in favor of Wells Fargo in all funds deposited in two of the Company’s money market accounts held at Wells Fargo. Restrictions on the money market accounts will be removed when the lines of credit are paid in full and have expired. The lines of credit are due and payable in full in April 2015.
Concentrations	Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at two major financial institutions as of December 31, 2014 and 2013. For the Company’s cash position of $49.7 million as of December 31, 2014, which includes restricted cash of $4.0 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance.

	Additional credit risk is related to the Company’s concentration of receivables. As of December 31, 2014, receivables were concentrated among two customers representing 95% of total net receivables and three customers as of December 31, 2013, representing 83%. For the years ended December 31, 2014, 2013 and 2012, revenue was concentrated among three customers representing 82%, 68% and 77% of total revenues, respectively. There were no supplier concentrations.
	During the year ended December 31, 2014, revenue earned from non-recurring sales in Germany accounted for approximately 10% of the Company’s revenue. During the year ended December 31, 2013, revenue earned from non-recurring sales in The Netherlands accounted for approximately 15% of the Company’s revenue. During 2012, no single foreign country accounted for more than 10% of the Company’s revenue.
Risk and Uncertainties	Risk and Uncertainties
	The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of the Company’s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals.
	Products developed by the Company require clearances from international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company.
	The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.
Accounts and Unbilled Receivables	Accounts and Unbilled Receivables
	Accounts receivable represent primarily commercial receivables associated with the Company’s service fees, license fees, product sales and receivables from U.S. government contracts. Accounts receivable amounted to $1.9 million and $2.0 million as of December 31, 2014 and 2013, respectively. Unbilled receivables represent reimbursable costs in excess of billings and, where applicable, accrued profit related to long-term government contracts for which revenue has been recognized, but the customer has not yet been billed. Unbilled receivables amounted to $0.3 million and $1.5 million as of December 31, 2014 and 2013, respectively.
	The Company evaluates the collectability of its receivables based on a variety of factors, including the length of time the receivables are past due, the financial health of its customers and historical experience. Based upon the review of these factors, the Company recorded an allowance for doubtful accounts of $0.6 million and $44 thousand at December 31, 2014 and 2013, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Financial instruments, including cash, cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, accrued liabilities and the lines of credit, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments. Other short-term investments are carried at fair value.
Inventories	Inventories
	Inventories consist of finished goods and are valued at the lower of cost or market. The Company regularly reviews inventories on hand to identify any inventory that has become obsolete or has a cost basis in excess of its expected net realizable value, as well as any inventory quantities in excess of expected requirements. No write-downs were recorded during the years ended December 31, 2014 or 2013.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from five to ten years with the exception of leasehold improvements which are amortized over the shorter of the lease term or their estimated useful life.
Intangible Assets	Intangible Assets
	Intangible assets include customer relationships, developed technology and trade names related to the Company’s asset acquisition. Intangible assets have been capitalized and amortized over the estimated useful life of 15 years, 20 years and 15 years, respectively.
Impairment of Long-Lived Assets Other Than Goodwill	Impairment of Long-Lived Assets Other Than Goodwill
	The Company assesses potential impairments to its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flow expected to result from the use of the assets. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset. No impairment was noted during the years ended December 31, 2014 and 2013.
Goodwill	Goodwill
	Goodwill is the excess of purchase price over the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed, in a business combination. The Company does not amortize goodwill. Instead, goodwill is tested for impairment annually and between annual tests if the Company becomes aware of an event or a change in circumstances that would indicate the carrying amount may be impaired. The Company performs its annual impairment testing on December 31st of each year. The Company will first assess qualitative factors to determine whether the existence of events or circumstances suggests that it is more likely than not that goodwill is impaired. Unless it is more likely than not that goodwill is impaired, the Company does not perform the two-step impairment test. The Company’s determination as to whether, and, if so, the extent to which, goodwill becomes impaired is highly judgmental and based on assumptions regarding its projected future operating results, changes in the manner of its use of the acquired assets or its overall business strategy and regulatory, market and economic environment and trends. No impairment was noted during the years ended December 31, 2014 and 2013.
Revenue	Revenue
	The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, government contracts and reagent protein products which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving milestones and for product royalties. The specifics of the Company’s significant agreements are detailed in Note 11—Significant Research and Development Agreements.
	The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement.
	Upfront, nonrefundable payments that do not have stand-alone value are recorded as deferred revenue and recognized as revenue over the estimated period of performance. Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.
	Revenue under service agreements are recorded as services are performed. These agreements do not require scientific achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement.
	The Company recognizes revenue for its cost plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under the Company’s government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred.
	The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. Where separate milestone payments do not meet these criteria, the Company recognizes revenue using a contingency-adjusted performance model over the period of performance. For the years ended December 31, 2014, 2013 and 2012, no revenue in connection with the achievement of milestones has been recognized.
	The Company’s reagent protein products are comprised of internally developed reagent protein products and those purchased from original manufacturers for resale. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the Company’s price to the buyer is fixed or determinable, and (4) collectability is reasonably assured. Revenue from sales transactions where the buyer has the right to return the product is recognized at the time of sale only if (1) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the Company, or the buyer is obligated to pay the Company and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the Company, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. Reagent product revenue amounted to $1.2 million, $3.3 million and $0.7 million for the years ended December 31, 2014, 2013 and 2012, respectively. As of December 31, 2014, the Company has had minimal product returns related to reagent protein product sales. However, given the nature of the products, the Company has deemed it prudent to reserve $10 thousand, $18 thousand and $16 thousand for warranty and return rights as of December 31, 2014, 2013 and 2012, respectively. The reserve is a component of accounts and unbilled receivables, net in the accompanying consolidated balance sheets.
	Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent.
Cost of Revenue	Cost of Revenue
	Cost of revenue includes costs incurred in connection with the execution of service contracts, as well as costs to manufacture or purchase, package and ship the Company’s reagent products.
Advertising	Advertising
	The Company expenses the cost of advertising when the advertising takes place. For each of the years ended December 31, 2013 and 2012, advertising expense was $0.3 million. There were no advertising expenditures in 2014.
Preclinical and Clinical Trial Accruals	Preclinical and Clinical Trial Accruals
	The Company’s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on the Company’s behalf.
	The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of series or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related series are recorded as prepaid expenses until the services are rendered.
Research and Development Expenses	Research and Development Expenses
	Research and development expenses are recognized as incurred and amounted to $4.1 million, $5.5 million and $1.8 million for the years ending December 31, 2014, 2013 and 2012, respectively.
Stock-Based Compensation	Stock-Based Compensation
	Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of estimated forfeitures, over the requisite service period. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award.
	The Company estimates the fair value of stock options and other equity-based compensation using a Black-Scholes option pricing model on the date of grant. The Black-Scholes valuation model requires multiple subjective inputs, which are discussed further in Note 12—Stock-Based Compensation. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally four years; however, certain provisions in the Company’s equity compensation plan provides for shorter and longer vesting periods under certain circumstances.
Comprehensive Loss	Comprehensive Loss
	Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.
Income Taxes	Income Taxes
	The Company files U.S. federal income tax returns and California, Massachusetts and Missouri state tax returns. To date, the Company not been audited by the Internal Revenue Service or any state income tax authority; however all tax years from and including 2009 remain open for examination by federal and state tax authorities. The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. A deferred income tax asset or liability is computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future tax benefit, if any, to be derived from tax credits and loss carryforwards. Deferred income tax expense or benefit would represent the net change during the year in the deferred income tax asset or liability. Deferred tax assets, if any, are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Net Loss per Share of Common Stock	Net Loss per Share of Common Stock
	Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, convertible notes payable, stock options and redeemable convertible preferred stock warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December 31, 2014, 2013 and 2012, diluted net loss per common share is the same as basic net loss per common share for those periods. For years ending December 31, 2013 and 2012, the Company had total accumulated dividends related to preferred stock in the amounts of $6.3 million and $4.6 million, respectively, which increased the net loss on a per share basis. There were no accumulated dividends related to preferred stock at December 31, 2014. Immediately prior to the IPO, the Company issued shares of common stock in connection with the payment of all accrued and unpaid dividends on the preferred stock upon the conversion of the convertible preferred stock to common stock. See Note 9—Common Stock and Preferred Stock.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements
	On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to avail itself of this extended transition period and, as a result, it will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies.
	In July 2013, the FASB issued guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. The adoption of this guidance did not have a material impact on the consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The effective date will be the first quarter of fiscal year 2018 using one of two retrospective application methods. The Company is currently evaluating the impact of the adoption of this accounting standard update on its financial statements.
Fair Value Measurements	Authoritative guidance defines fair value, establishes a framework for measuring fair value in U.S. GAAP and requires disclosures about fair value measurements.
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:

		•	Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at December 31, 2014 and December 31, 2013 included the Company’s cash, cash equivalents and investments in certificates of deposit. There were no Level 1 liabilities;

		•	Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at December 31, 2014 or December 31, 2013; and

		•	Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at December 31, 2014 or December 31, 2013.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Sales Revenue	A breakdown of the Company’s net revenue from U.S. and non-U.S. sources for the years ended December 31, 2014, 2013 and 2012 is as follows:


		Years Ended December 31,
		2014		2013		2012
		(in thousands)
	US Revenue	$	8,782	$	8,435	$	10,298
	Non-US Revenue		1,862		3,479		996

		$	10,644	$	11,914	$	11,294

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Cash and Investments Measured at Fair Value on Recurring Basis	The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of December 31, 2014 and 2013, were determined using the inputs described above and are as follows:


					Fair Value Measurements at Reporting
					Data Using
		Total			Quoted Prices			Significant		Significant
					in Active			Other		Unobservable
					Markets for			Observable		Inputs
					Identical Assets			Inputs		(Level 3)
					(Level 1)			(Level 2)
		(in thousands)
	December 31, 2014
	Classified as current assets:
	Cash and money market funds	$	49,677		$	49,677		$	—	$	—
	Certificates of deposit		—			—			—		—

	Total		49,677			49,677			—		—
	Less cash, cash equivalents and restricted cash		(49,677	)		(49,677	)		—		—

	Total investments	$	—		$	—		$	—	$	—

	December 31, 2013
	Classified as current assets:
	Cash and money market funds	$	7,983		$	7,983		$	—	$	—
	Certificates of deposit		1,250			1,250			—		—

	Total		9,233			9,233			—		—
	Less cash, cash equivalents and restricted cash		(7,983	)		(7,983	)		—		—

	Total investments	$	1,250		$	1,250		$	—	$	—

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following:


		December 31,
		2014			2013
		(in thousands)
	Furniture and equipment	$	157		$	32
	Computers and IT equipment		190			86
	Purchased software		686			674
	Lab and research equipment		2,837			2,695
	Leasehold improvements		348			336
	Other fixed assets		35			35

	Total property and equipment, gross		4,253			3,858
	Less: accumulated depreciation and amortization		(1,943	)		(1,529	)

	Total property and equipment, net	$	2,310		$	2,329


	For the years ended December 31, 2014, 2013 and 2012, total depreciation and amortization expense was $0.5 million, $0.5 million and $0.4 million, respectively, which is included in selling, general and administrative expenses and research and development in the accompanying consolidated statements of operations as follows:


		Years ended December 31,
		2014			2013			2012
		(in thousands)
	Selling, general and administrative	$	366		$	285		$	357
	Research and development		99			177			80

	Total depreciation and amortization expense	$	465		$	462		$	437

Notes_Receivable_from_Related_1

Notes Receivable from Related Parties (Tables)	12 Months Ended
Notes Receivable from Related Parties (Tables)	Dec. 31, 2014
Related Party Transactions [Abstract]
Composition of Notes Receivable Balance	The composition of notes receivable balance as of December 31, 2014 and 2013 was as follows:


		December 31,
		2014		2013
		(in thousands)
	Principal balance	$	—	$	87
	Accrued and unpaid interest		—		8

	Total notes receivable	$	—	$	95

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets consisted of the following:


		December 31,
		2014			2013
		(in thousands)
	Customer relationships	$	3,750		$	3,750
	Developed technology		4,400			4,400
	Trade names		910			910

	Gross intangible assets		9,060			9,060
	Less: Accumulated amortization		(2,697	)		(2,167	)

	Total intangible assets, net	$	6,363		$	6,893

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
Accrued Liabilities (Tables)	Dec. 31, 2014
Payables and Accruals [Abstract]
Components of Accrued Liabilities	Accrued liabilities consisted of the following:


		December 31,
		2014		2013
		(in thousands)
	Accrued vacation	$	379	$	321
	Deferred rent		247		238
	Accrued bonuses		913		735
	Other accrued employee-related liabilities		125		36
	Accrued professional fees		221		191
	Accrued supplier liability		198		747
	Accrued subcontractor costs		292		526
	Other accrued liabilities		258		159

	Total accrued liabilities	$	2,633	$	2,953

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Rent Expense	Rent expense was $0.4 million for each of the years ended December 31, 2014, 2013 and 2012, which is included in selling, general and administrative and research and development expenses in the accompanying consolidated statements of operations as follows:


		Years Ended December 31,
		2014		2013		2012
		(in thousands)
	Selling, general and administrative	$	279	$	184	$	278
	Research and development		99		175		81

	Total rent expense	$	378	$	359	$	359

Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Noncancelable Leasing Arrangements, Including Facilities Lease	As of December 31, 2014, the total estimated future annual minimum lease payment obligations under the Company’s noncancelable leasing arrangements, including the facilities lease described above, are as follows:


		Payment Amounts
		Operating		Capital Leases		Total
		Leases		Capital Leases		Total
		(in thousands)
	2015	$	586	$	49	$	635
	2016		608		49		657
	2017		624		48		672
	2018		558		—		558
	2019		574		—		574
	Thereafter		2,628		—		2,628

	Total future minimum lease payments	$	5,578	$	146	$	5,724

Common_Stock_and_Preferred_Sto1

Common Stock and Preferred Stock (Tables)	12 Months Ended
Common Stock and Preferred Stock (Tables)	Dec. 31, 2014
Equity [Abstract]
Summary of Cumulative Dividends	As of December 31, 2013, no dividends had been declared or paid. Based on the IPO price of $6.00 per share and the offering closing on July 29, 2014, we issued 1.217,784 shares of common stock to holders of our outstanding preferred stock prior to the offering in satisfaction of these accrued dividends through July 28, 2014. Cumulative dividends as of July 28, 2014 and December 31, 2013 were as follows:


		Cumulative as of July 28, 2014				Cumulative as of
		Cumulative as of July 28, 2014				December 31, 2013
		Dividends		Dividends		Dividends		Dividends per
		Dividends		per Share		Dividends		Share
		(in thousands except dividends per share)
	Series A-2	$	4,457	$	1.25	$	3,815	$	1.07
	Series A-1		2,850	$	0.57		2,470	$	0.5

		$	7,307			$	6,285

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Assumptions used to Estimate Fair Value of Stock Options	The following assumptions were used to estimate the fair value of stock options:


		Years Ended December 31,
		2014		2013				2012
	Risk-free interest rate	1.7 – 2.0%			1.2	%			1	%
	Expected volatility	48.7 – 55.0%			54.4	%			47.1	%
	Expected dividend yield	0.00%			0	%			0	%
	Expected life of options in years	5.3-6.1			6.1				6
Stock Option Transactions under Plan	Stock option transactions under the Plan during the years ended December 31, 2014, 2013 and 2012 are as follows:


		Number of				Weighted				Weighted		Aggregate
		Options				Average				Average		Intrinsic Value
		(in thousands)				Exercise Price				Remaining		(in thousands)
										Contractual
										Term (in years)
	Outstanding at January 1, 2012		705			$	0.33
	Granted		139				1.49
	Exercised		(17	)			0.31
	Cancelled (forfeited)		(17	)			0.31

	Outstanding at December 31, 2012		810				0.53
	Granted		36				1.5
	Exercised		(62	)			0.39
	Cancelled (forfeited)		(26	)			0.89

	Outstanding at December 31, 2013		758				0.57
	Granted		611				8.89
	Exercised		(105	)			0.53
	Cancelled (forfeited)		(32	)			1.49

	Outstanding at December 31, 2014		1,232			$	4.68				7.63	$	4,301

	Vested and expected to vest at December 31, 2014		1,139			$	4.39				7.48	$	4,225
	Vested and exercisable at December 31, 2014		588			$	0.78				5.55	$	3,840

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Income Tax Benefit	The components of the income tax benefit are as follows:


		Years Ended December 31,
		2014			2013			2012
		(in thousands)
	Income tax benefit
	Current	$	1,047		$	1,469		$	3,695
	Deferred		(1,047	)		1,202			(1,654	)

	Total benefit	$	—		$	2,671		$	2,041

Components of Deferred Tax Assets	Significant components of the Company’s deferred tax assets as of December 31, 2014 and 2013 are shown below. A valuation allowance of $4.4 million and $0.4 million as of December 31, 2014 and 2013, respectively, has been established to offset deferred tax assets, as realization of such assets is uncertain.


		December 31,
		2014			2013
		(in thousands)
	Deferred tax assets
	Net operating losses	$	5,731		$	2,434
	Deferred revenue		80			180
	Other		1,837			1,241

	Total deferred tax assets		7,648			3,855

	Deferred tax liabilities
	Depreciation and amortization		(731	)		(772	)
	Intangible assets		(2,550	)		(2,709	)

	Total deferred tax liabilities		(3,281	)		(3,481	)

	Valuation allowance		(4,367	)		(374	)

	Net deferred tax liability	$	—		$	—

Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate	A reconciliation of the Company’s effective tax rate and federal statutory tax rate at December 31, 2014, 2013 and 2012 is as follows:


		December 31,
		2014						2013					2012
		(in thousands)
	Federal income taxes	$	(3,330	)		34	%	$	2,278		34.00	%	$	1,579		34.00	%
	State income taxes		(567	)		5.78	%		390		5.81	%		270		5.81	%
	Permanent items		126			(1.29	)%		(29	)	(0.43	)%		(24	)	(0.52	)%
	Valuation Allowance		3,994			(40.75	)%		(374	)	(5.58	)%		—		—	%
	Other		(223	)		2.26	%		406		6.06	%		216		4.66	%

	Total income tax benefit	$	—			0	%	$	2,671		39.86	%	$	2,041		43.95	%

Net_Loss_Per_Share_of_Common_S1

Net Loss Per Share of Common Stock (Tables)	12 Months Ended
Net Loss Per Share of Common Stock (Tables)	Dec. 31, 2014
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:


		December 31,
		2014			2013			2012
		(in thousands, except per share data)
	Net loss	$	(9,794	)	$	(4,062	)	$	(2,593	)
	Effective preferred stock dividend		—			(1,695	)		(1,589	)

	Net loss plus preferred stock dividend—basic and diluted	$	(9,794	)	$	(5,757	)	$	(4,182	)

	Weighted average shares used to compute basic and diluted net loss per share		9,441			1,531			1,474

	Basic and diluted net loss per common share	$	(1.04	)	$	(3.76	)	$	(2.84	)

Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding	The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding:


		December 31,
		2014			2013
	Redeemable convertible preferred stock		—			8,634,847
	Options to purchase common stock		1,231,886			757,805

Quarterly_Financial_Data_Table

Quarterly Financial Data (Tables)	12 Months Ended
Quarterly Financial Data (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Data	The following is a summary of the quarterly results of the Company for the years ended December 31, 2014 and 2013 (unaudited):


			First			Second			Third			Fourth			Year Ended
			Quarter			Quarter			Quarter			Quarter			December 31
			(in thousands, except for per share data)
	2014
	Revenues		$	2,558		$	3,266		$	2,801		$	2,019		$	10,644
	Cost of revenues			1,908			2,544			1,579			1,202			7,233

	Gross profit			650			722			1,222			817			3,411
	Operating expenses			2,173			2,884			3,698			4,373			13,128
	Interest expense, net			18			21			19			19			77
	Income tax expense (benefit)			1			—			—			(1	)		—

	Net loss			(1,542	)		(2,183	)		(2,495	)		(3,574	)		(9,794	)

	Effective preferred stock dividends(1)			(435	)		(447	)		—			—

	Net loss attributable to common stockholders			(1,977	)		(2,630	)		(2,495	)		(3,574	)		(9,794	)

	Net loss per share:
	Basic and Diluted		$	(1.28	)	$	(1.67	)	$	(0.16	)	$	(0.18	)	$	(1.04	)
	Shares used in the calculation of net loss per share:
	Basic and Diluted			1,548			1,571			15,319			20,388			9,441
	2013
	Revenues		$	3,385		$	2,309		$	1,989		$	4,231		$	11,914
	Cost of revenues			2,029			1,306			1,153			1,935			6,423

	Gross profit			1,356			1,003			836			2,296			5,491
	Operating expenses			2,563			2,948			3,635			3,042			12,188
	Interest expense, net			1			9			7			19			36
	Income tax benefit			(482	)		(777	)		(1,116	)		(296	)		(2,671	)

	Net loss			(726	)		(1,177	)		(1,690	)		(469	)		(4,062	)

	Effective preferred stock dividends(1)			(408	)		(419	)		(430	)		(438	)		(1,695	)

	Net loss attributable to common stockholders			(1,134	)		(1,596	)		(2,120	)		(907	)		(5,757	)

	Net loss per share:
	Basic and Diluted		$	0.76		$	(1.04	)	$	(2.08	)	$	(0.59	)	$	(3.76	)
	Shares used in the calculation of net loss per share:
	Basic and Diluted			1,497			1,542			1,019			1,542			1,531

	-1	The holders of our convertible preferred stock were entitled to cumulative dividends prior and in preference to our common stock. Because the holders of our convertible preferred stock were entitled to participate in dividends, net loss attributable to common stockholders was equal to net loss adjusted for convertible preferred stock dividends for the period. Immediately upon the closing of our IPO, all outstanding shares of our redeemable convertible preferred stock, or our convertible preferred stock, were automatically converted into an aggregate of 8,634,847 shares of common stock and these holders were issued 1,217,784 shares of common stock for the payment of all accrued and unpaid dividends through July 28, 2014 in connection with such conversion based on the initial public offering price of $6.00 per share and the offering closing on July 29, 2014. See Note 15 to our financial statements for a description of the method used to compute basic and diluted net loss per share attributable to common stockholders and for a description of convertible preferred stock, respectively. Please refer to Note 9 of our consolidated financial statements for an explanation of the cumulative preferred stock dividends.

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended			1 Months Ended
	Jun. 27, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2014	Jul. 28, 2014
	Jun. 27, 2014	Segments	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2014	Jul. 28, 2014
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Reverse stock split ratio	0.3556
Common stock shares issued		20,405,066	1,541,781
Common stock issued in connection with payment of dividends		1,217,784
Number of operating segment		1
Line of credit facility, Maximum borrowing capacity		$3,900,000
Restricted cash		3,955,000	4,029,000
Accounts receivable		1,900,000	2,000,000
Unbilled receivables		300,000	1,500,000
Allowance for doubtful accounts receivable		600,000	44,000
Inventory write downs		0	0
Impairment of long-lived assets		0	0
Impairment of goodwill		0	0
Revenue recognized		0	0	0
Product return policy period		30 days
Advertising expense		0	300,000	300,000
Research and development expenses		4,125,000	5,490,000	1,792,000
Requisite service period award		4 years
Total accumulated dividends related to preferred stock		0	6,285,000	4,600,000		7,307,000
Trade Names [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful life		15 years
Customer Relationships [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful life		15 years
Developed Technology [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Intangible assets estimated useful life		20 years
Minimum [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives		5 years
Maximum [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives		10 years
Credit Availability Concentration Risk [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Cash		49,700,000
Restricted cash		3,955,000
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of customers accounted for receivables		2	3
Concentration of risk percentage		95.00%	83.00%
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of customers accounted for revenue		3	3	3
Concentration of risk percentage		82.00%	68.00%	77.00%
Sales Revenue, Net [Member] \| Geographic Concentration Risk [Member] \| GERMANY
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage		10.00%
Sales Revenue, Net [Member] \| Geographic Concentration Risk [Member] \| NETHERLANDS
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage			15.00%
Sales Revenue, Net [Member] \| Geographic Concentration Risk [Member] \| Foreign Country [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of country accounted				0
Sales Revenue, Net [Member] \| Geographic Concentration Risk [Member] \| Foreign Country [Member] \| Minimum [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage				10.00%
Reagent Product [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Product revenue		1,200,000	3,300,000	700,000
Reagent Protein Product [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Warranty reserve accrual		10,000	18,000	16,000
Federal [Member] \| Earliest Tax Year [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Tax years from and including remain open for examination		2009
State [Member] \| Earliest Tax Year [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Tax years from and including remain open for examination		2009
IPO [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock shares issued					8,333,333
Common stock price, per share					$6
Proceeds from issuance initial public offering					52,600,000
Offering expense					2,000,000
Common stock issued in connection with payment of dividends					1,217,784
Common stock repurchased					423,185
Common stock purchase price					$0.31
Number of shares forfeited					100,000
IPO [Member] \| Redeemable Preferred to Common Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Convertible preferred stock shares converted to common stock					8,634,857
IPO [Member] \| Redeemable Convertible Preferred Stock [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock issued in connection with payment of dividends					1,217,784
Underwriters' Option [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Issuance of stock (in shares)					1,095,751
Wells Fargo 2012 LOC [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Line of credit facility, Maximum borrowing capacity		1,500,000
Wells Fargo 2013 LOC [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Line of credit facility, Maximum borrowing capacity		$2,400,000

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies - Summary of Sales Revenue (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]
Revenue	$2,019	$2,801	$3,266	$2,558	$4,231	$1,989	$2,309	$3,385	$10,644	$11,914	$11,294
Geographic Concentration Risk [Member] \| US [Member]
Concentration Risk [Line Items]
Revenue									8,782	8,435	10,298
Geographic Concentration Risk [Member] \| Non - US [Member]
Concentration Risk [Line Items]
Revenue									$1,862	$3,479	$996

Fair_Value_Measurements_Cash_a

Fair Value Measurements - Cash and Investments Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and money market funds	$49,677	$7,983
Assets fair value disclosure	49,677	9,233
Less cash, cash equivalents and restricted cash	-49,677	-7,983
Total investments		1,250
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value disclosure		1,250
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and money market funds	49,677	7,983
Assets fair value disclosure	49,677	9,233
Less cash, cash equivalents and restricted cash	-49,677	-7,983
Total investments		1,250
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets fair value disclosure		$1,250

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$4,253	$3,858
Less: accumulated depreciation and amortization	-1,943	-1,529
Total property and equipment, net	2,310	2,329
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	157	32
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	190	86
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	686	674
Research and Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	2,837	2,695
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	348	336
Other Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$35	$35

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Property and equipment assets under capital lease	$200	$3
Accumulated depreciation related to assets under capital lease	3	2
Total depreciation and amortization expense	$465	$462	$437

Property_and_Equipment_Depreci

Property and Equipment - Depreciation and Amortization Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	$465	$462	$437
Selling, General and Administrative Expenses [Member]
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	366	285	357
Research and Development [Member]
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expense	$99	$177	$80

Notes_Receivable_from_Related_2

Notes Receivable from Related Parties - Additional Information (Detail) (Officers and Employees [Member], USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2014	Jan. 21, 2010
Officers and Employees [Member]
Related Party Transaction [Line Items]
Principal amount of note issued			$87
Debt instrument due date, Description		The principal balance of the Notes were due together with accrued and unpaid interest on the earliest of (i) January 21, 2015, (ii) upon the occurrence and during the continuance of an event of default under the Notes, (iii) the closing of a corporate event affecting the existing ownership structure, and (iv) the sale of any shares of common stock of the Company held by the maker to a third party.
Interest rate			2.45%
Charge for write-offs	$157

Notes_Receivable_from_Related_3

Notes Receivable from Related Parties - Composition of Notes Receivable Balance (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Related Party Transaction [Line Items]
Total notes receivable	$95
Officers and Employees [Member]
Related Party Transaction [Line Items]
Principal balance	87
Accrued and unpaid interest	8
Total notes receivable	$95

Intangible_Assets_Summary_of_I

Intangible Assets - Summary of Intangible Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	$9,060	$9,060
Less: Accumulated amortization	-2,697	-2,167
Total intangible assets, net	6,363	6,893
Trade Names [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	910	910
Customer Relationships [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	3,750	3,750
Developed Technology [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross intangible assets	$4,400	$4,400

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$529	$531	$531
Five Years Estimated [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	500
Selling, General and Administrative Expenses [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$500	$500	$500

Accrued_Liabilities_Components

Accrued Liabilities - Components of Accrued Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]
Accrued vacation	$379	$321
Deferred rent	247	238
Accrued bonuses	913	735
Other accrued employee-related liabilities	125	36
Accrued professional fees	221	191
Accrued supplier liability	198	747
Accrued subcontractor costs	292	526
Other accrued liabilities	258	159
Total accrued liabilities	$2,633	$2,953

Lines_of_Credit_Obligation_Add

Lines of Credit Obligation - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 24, 2014	Apr. 02, 2014	Jan. 31, 2015
Line of Credit Facility [Line Items]
Line of credit facility, Maximum borrowing capacity	$3,900,000
Line of credit facility, covenant compliance	The Company was not in compliance with covenants pertaining to (i) the delivery of its 2012 audit report, which was delivered before May 15, 2014 along with the Company's 2013 audit report; (ii) the pre-approval for certain capital expenditures; and (iii) the pre-approval required for entering into a lease for a commercial copier/printer.
Line of credit covenant, operating lease expenses allowed to be incurred	600,000
Line of credit covenant description	On June 24, 2014, the Company entered into an amendment to the credit facilities which allows the Company to (i) make additional investments in fixed assets in any fiscal year; (ii) incur operating lease expenses in any fiscal year up to $0.6 million; and (iii) declare or pay any dividend or distribution either in cash, stock or any other property, or redeem, retire, repurchase or otherwise acquire any shares of any class of stock in connection with the Company's IPO.
Line of credit total outstanding amount	3,813,000
Interest expense	85,000	43,000	14,000
Maximum [Member]
Line of Credit Facility [Line Items]
Line of credit covenant, common stock repurchase allowed					500,000
Line of credit covenant, operating lease expenses allowed to be incurred				600,000
Wells Fargo 2012 LOC [Member]
Line of Credit Facility [Line Items]
Line of credit facility, Maximum borrowing capacity	1,500,000
Line of credit total outstanding amount	1,400,000
Line of credit bearing a fixed interest rate	2.25%
Wells Fargo 2012 LOC [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of credit facility, basis spread	2.00%
Wells Fargo 2013 LOC [Member]
Line of Credit Facility [Line Items]
Line of credit facility, Maximum borrowing capacity	2,400,000
Line of credit total outstanding amount	2,400,000
Wells Fargo 2013 LOC [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Line of credit bearing a fixed interest rate	2.38%
Wells Fargo 2013 LOC [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Line of credit bearing a fixed interest rate	2.25%
Subsequent Event [Member]
Line of Credit Facility [Line Items]
Line of credit covenant, operating lease expenses allowed to be incurred						$900,000

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended
	Sep. 30, 2014	Jun. 30, 2010	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	sqft	Jun. 30, 2010	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Contingencies And Commitments [Line Items]
Initial term of lease		10 years
Lease commencement date			Apr-11
Description of lease agreement terms			Under the terms of the Lease, the Company pays annual base rent, subject to an annual fixed percentage increase, plus its share of common operating expenses.
Annual base rent abatement percentage			50.00%
Extend term of lease			Operating lease agreement to extend the term of the lease for an additional three years through March 31, 2024
Lease additional facilities	7,315
Increase in estimated rent payments over the life of lease	$2,900,000
Additional term of lease agreement	3 years
Operating lease expiration date	31-Mar-24
Rent expense			378,000	359,000	359,000
Long-term contractual obligations			5,724,000
Long-term contractual obligations payment period			12 months
Indemnification Agreements [Member]
Contingencies And Commitments [Line Items]
Number of pending legal proceedings			0	0
Office And Lab Equipment [Member]
Contingencies And Commitments [Line Items]
Operating and capital lease expiration dates			Various dates through December 2019.
New Space [Member]
Contingencies And Commitments [Line Items]
Increase in estimated rent payments over the life of lease	1,500,000
Existing Space [Member]
Contingencies And Commitments [Line Items]
Increase in estimated rent payments over the life of lease	$1,400,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Rent Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Lease Rent Expense [Line Items]
Total rent expense	$378	$359	$359
Selling, General and Administrative Expenses [Member]
Schedule of Lease Rent Expense [Line Items]
Total rent expense	279	184	278
Research and Development [Member]
Schedule of Lease Rent Expense [Line Items]
Total rent expense	$99	$175	$81

Commitments_and_Contingencies_3

Commitments and Contingencies - Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Noncancelable Leasing Arrangements, Including Facilities Lease (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, 2015	$586
Operating Leases, 2016	608
Operating Leases, 2017	624
Operating Leases, 2018	558
Operating Leases, 2019	574
Operating Leases, Thereafter	2,628
Operating Leases, Total future minimum lease payments	5,578
Capital Leases, 2015	49
Capital Leases, 2016	49
Capital Leases, 2017	48
Capital Leases, 2018	0
Capital Leases, 2019	0
Capital Leases, Thereafter	0
Capital Leases,Total future minimum lease payments	146
Total future minimum lease payments, 2015	635
Total future minimum lease payments, 2016	657
Total future minimum lease payments, 2017	672
Total future minimum lease payments, 2018	558
Total future minimum lease payments, 2019	574
Total future minimum lease payments, Thereafter	2,628
Total future minimum lease payments	$5,724

Common_Stock_and_Preferred_Sto2

Common Stock and Preferred Stock - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended		1 Months Ended
	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2014
	Jun. 30, 2014	Vote	Dec. 31, 2013	Jul. 31, 2014
Class of Stock [Line Items]
Common stock issued in connection with payment of dividends		1,217,784
Votes entitled for every common stock		1
Preferred stock authorized		10,000,000
Preferred stock, redemption terms		The Series A-1 and A-2 preferred stock had a contingent redemption feature allowing redemption by the holders at any time after December 31, 2014 upon the affirmative vote of sixty-six and two thirds (66 2b3%) of the holders. As the event that would trigger the redemption of the redeemable convertible preferred stock was not solely within the Companybs control, the redeemable convertible preferred stock has been classified as mezzanine equity (outside of permanent equity) on the Companybs consolidated balance sheet. The shares are to be redeemed by paying cash in an amount per share equal to the greater of (i) the Series A original issue price and any Series A dividends accrued but unpaid and (ii) the then-current fair market value of such shares.
Affirmative vote required for redemption		66.67%
Adjustments made to the redemption values	$800,000		$71,000,000
Issuance of dilutive common stock			0
Dividend declared or paid			$0
IPO [Member]
Class of Stock [Line Items]
Common stock issued in connection with payment of dividends				1,217,784
Number of shares forfeited				100,000
Common stock price, per share				$6
Offering closing date		29-Jul-14
IPO [Member] \| Redeemable Preferred to Common Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock shares converted to common stock				8,634,857
Preferred Stock Series A-1 [Member]
Class of Stock [Line Items]
Preferred stock dividend rate, cumulative percentage		4.00%
Preferred stock conversion ratio for each share		0.91966
Convertible preferred stock shares converted to common stock			0
Preferred Stock Series A-2 [Member]
Class of Stock [Line Items]
Preferred stock dividend rate, cumulative percentage		8.00%
Preferred stock conversion ratio for each share		1.1406
Convertible preferred stock shares converted to common stock			0
Redeemable Convertible Preferred Stock [Member] \| IPO [Member]
Class of Stock [Line Items]
Common stock issued in connection with payment of dividends				1,217,784

Common_Stock_and_Preferred_Sto3

Common Stock and Preferred Stock - Summary of Cumulative Dividends (Detail) (USD $)	Dec. 31, 2014	Jul. 28, 2014	Dec. 31, 2013	Dec. 31, 2012
Dividends Payable [Line Items]
Dividends	$0	$7,307,000	$6,285,000	$4,600,000
Preferred Stock Series A-2 [Member]
Dividends Payable [Line Items]
Dividends		4,457,000	3,815,000
Dividends per Share		$1.25	$1.07
Preferred Stock Series A-1 [Member]
Dividends Payable [Line Items]
Dividends		$2,850,000	$2,470,000
Dividends per Share		$0.57	$0.50

Commitment_to_Repurchase_Stock1

Commitment to Repurchase Stock - Additional Information (Detail) (USD $)	12 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Jul. 31, 2014	Dec. 01, 2009
Equity, Class of Treasury Stock [Line Items]
Total cost of repurchase	$131
Common Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock purchase price		$0.31
Shares repurchased	423,000	423,185
Total cost of repurchase		$131
Common Stock [Member] \| Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Number of shares authorized to be repurchased			423,185
Share price			$0.31

Significant_Research_and_Devel1

Significant Research and Development Agreements - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended			1 Months Ended				12 Months Ended
	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Jul. 31, 2010	Sep. 30, 2012	Jul. 31, 2012	Dec. 31, 2009
	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Option	Option	Jul. 31, 2012	Dec. 31, 2009
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Share of revenues and costs percentage	49.00%
Research service fees		$4,125,000	$5,490,000	$1,792,000
Funding Agreements [Member] \| U.S. Department of Health and Human Services [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Reimbursable costs		5,000,000	2,300,000	2,500,000
Number of follow on options						5
Total amount of contract					25,200,000
Revenue of services performed		6,600,000	4,200,000	3,700,000
Agreement termination description		This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 whereupon BARDA may immediately terminate the agreement early for convenience, or request the Company to stop all or any part of the work for a period of at least 90 days.
Funding Agreements [Member] \| National Institute of Allergy and Infectious Diseases [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Reimbursable costs		500,000	300,000	3,000
Number of follow on options							13
Total amount of contract							22,900,000
Revenue of services performed		1,000,000	800,000	100,000
Agreement termination description		This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 wherein NIAID may immediately terminate the agreement early for convenience, or request the Company to stop all or any part of the work for a period of at least 90 days.
Amount of contract eligible for payment		3,000,000			3,000,000		2,200,000
Base program period							14 months
Funding Agreements [Member] \| Crucell [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total amount of contract								1,800,000
Funding Agreements [Member] \| Leidos [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total amount of contract									8,400,000
Revenue of services performed		200,000	2,100,000	2,200,000
Contract term for services									5 years
Deferred revenue		0	200,000		0
Funding Agreements [Member] \| Stelis Biopharma Private Limited [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Reimbursable costs				200,000
Share of revenues and costs percentage	51.00%
Investment in join venture		0			0
Collaboration Agreements [Member] \| BoehringerIngelheim International Gmbh [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue of services performed		1,000,000	5,000	0
Deferred revenue		0	1,000,000		0
Collaboration agreement transaction period		3 years
Number of proteins for commercial license obtained		4
License revenue associated with technology maintenance fee		0	200,000	200,000
Fees received under program		400,000
Reduction in service guarantee fee		400,000
Collaboration Agreements [Member] \| BoehringerIngelheim International Gmbh [Member] \| Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Guarantee fee		600,000
Collaboration Agreements [Member] \| BoehringerIngelheim International Gmbh [Member] \| Protein Expression Program [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Guarantee fee		1,050,000
Collaboration Agreements [Member] \| MedImmune, LLC [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination description		MedImmune was entitled to terminate the research term of the agreement upon 90 days prior written notice. Early termination required certain minimum payment amounts, depending on the date of the early termination. In February 2013, MedImmune notified the Company that they were terminating the contract early due to a lack of microbial based portfolio projects that could use the Pfnex Expression Technology.
Technology access fees and service revenue		0	1,200,000	2,800,000
Technology fee		3,000,000
Research service fees		2,400,000
Income from revised technology access fees		$1,750,000

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	1 Months Ended			12 Months Ended			0 Months Ended
	Jul. 31, 2014	Jun. 30, 2014	Jan. 31, 2010	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted to purchase shares		259,224		611,000	36,000	139,000
Outstanding options				1,232,000	758,000	810,000	1,232,000	705,000
Shares annual increase terms				Annual increase on the first day of each fiscal year beginning in 2015 and ending with and including the 2018 fiscal year, equal to the least of (i) 1,356,219 shares; (ii) 2.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the board of directors may determine.
Annually shares increase percent	2.50%
Weighted average remaining contractual term				7 years 7 months 17 days
Shares annual increase terms under ESPP				Annual increases in the number of shares available for sale under the ESPP on the first day of each fiscal year beginning in 2015, equal to the least of (i) 355,618 shares; (ii) 1.5% of the outstanding shares of the common stock on the last day of the immediately preceding fiscal year; or (iii) such other amount as may be determined by the administrator. No shares have been purchased under the ESPP as of December 31, 2014.
Annually shares increase percent under ESPP	1.50%
Stock based compensation expense associated with stock options				$400,000	$52,000	$28,000
Common stock issued in connection with payment of dividends				1,217,784
Weighted average grant date fair value, granted				$4.60	$1.04	$0.67
Fair value of shares vested during the period				137,000	57,000	28,000
Proceeds from stock options exercised				56,000	24,000	5,000
Unrecognized compensation cost related to unvested stock options				2,100,000			2,100,000
Unrecognized compensation cost related to unvested stock options, weighted average period for recognition				3 years 4 months 24 days
Aggregate intrinsic value, excess of exercise price over estimated fair value of options exercised				3,840,000	89,000	21,000	3,840,000
Options granted, weighted average exercise price		$11.59		$8.89	$1.50	$1.49
Restricted stock, Granted shares			1,034,850	0	0	0
Restricted stock, Granted estimated value			$0.31
Restricted stock, granted amount			300,000
Restricted stock, vested shares					1,034,850
Restricted stock, stock based compensation expense				$0	$74,000	$80,000
2009 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted to purchase shares							0
Shares reserved for issuance				1,100,000			1,100,000
Outstanding options				900,000			900,000
Weighted average remaining contractual term				10 years
Share-based compensation arrangement by share-based payment award, award vesting period				4 years
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	1,356,219
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	355,618
Shares purchased under ESPP				0
Maximum [Member] \| Scenario, May be added to the 2014 Plan [Member] \| 2009 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of previously granted shares that can be added	961,755
Incentive Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term				5 years
Percentage of voting power				10.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term				7 years 7 months 6 days
Share-based compensation arrangement by share-based payment award, award vesting period		4 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period				4 years

StockBased_Compensation_Assump

Stock-Based Compensation - Assumptions used to Estimate Fair Value of Stock Options (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	1.70%
Risk-free interest rate, maximum	2.00%
Risk-free interest rate		1.20%	1.00%
Expected volatility, minimum	48.70%
Expected volatility, maximum	55.00%
Expected volatility		54.40%	47.10%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life of options in years		6 years 1 month 6 days	6 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options in years	5 years 3 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options in years	6 years 1 month 6 days

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Option Transactions under Plan (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Options, beginning balance		758,000	810,000	705,000
Number of Options, Granted	259,224	611,000	36,000	139,000
Number of Options, Exercised		-105,000	-62,000	-17,000
Number of Options, Cancelled (forfeited)		-32,000	-26,000	-17,000
Number of Options, ending balance		1,232,000	758,000	810,000
Weighted Average Exercise Price, Outstanding, beginning balance		$0.57	$0.53	$0.33
Number of Options, Vested and expected to vest at December 31, 2014		1,139,000
Weighted Average Exercise Price, Granted	$11.59	$8.89	$1.50	$1.49
Number of Options, Vested and exercisable at December 31, 2014		588,000
Weighted Average Exercise Price, Exercised		$0.53	$0.39	$0.31
Weighted Average Exercise Price, Cancelled (forfeited)		$1.49	$0.89	$0.31
Weighted Average Exercise Price, Outstanding, ending balance		$4.68	$0.57	$0.53
Weighted Average Exercise Price, Vested and expected to vest at December 31, 2014		$4.39
Weighted Average Exercise Price, Vested and exercisable at December 31, 2014		$0.78
Weighted Average Remaining Contractual Term (in years), Outstanding		7 years 7 months 17 days
Weighted Average Remaining Contractual Term (in years), Vested and expected to vest at December 31, 2014		7 years 5 months 23 days
Weighted Average Remaining Contractual Term (in years), Vested and exercisable at December 31, 2014		5 years 6 months 18 days
Aggregate Intrinsic Value, Outstanding		$4,301
Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2014		4,225
Aggregate Intrinsic Value, Vested and exercisable at December 31, 2014		$3,840	$89	$21

Income_Taxes_Components_of_Inc

Income Taxes - Components of Income Tax Benefit (Detail) (USD $)	3 Months Ended						12 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income tax benefit
Current							$1,047,000	$1,469,000	$3,695,000
Deferred							-1,047,000	1,202,000	-1,654,000
Total benefit	$1,000	($1,000)	$296,000	$1,116,000	$777,000	$482,000	$0	$2,671,000	$2,041,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended						12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]
Income tax benefit (expense)	$1,000	($1,000)	$296,000	$1,116,000	$777,000	$482,000	$0	$2,671,000	$2,041,000
Accrued interest or penalties	0		0				0	0
Valuation allowance	4,367,000		374,000				4,367,000	374,000
Uncertain tax positions	0						0
Interest or penalties expense							0	0	0
Federal [Member]
Income Tax Disclosure [Line Items]
Tax credit carryforward amount	467,000						467,000
Operating loss carryforwards	14,200,000						14,200,000
Operating loss carryforwards expiration year							2032
Federal [Member] \| Earliest Tax Year [Member]
Income Tax Disclosure [Line Items]
Tax years from and including remain open for examination							2009
State [Member]
Income Tax Disclosure [Line Items]
Tax credit carryforward amount	328,000						328,000
Operating loss carryforwards	$15,800,000						$15,800,000
Operating loss carryforwards expiration year							2029
State [Member] \| Earliest Tax Year [Member]
Income Tax Disclosure [Line Items]
Tax years from and including remain open for examination							2009

Income_Taxes_Components_of_Def

Income Taxes - Components of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets
Net operating losses	$5,731	$2,434
Deferred revenue	80	180
Other	1,837	1,241
Total deferred tax assets	7,648	3,855
Deferred tax liabilities
Depreciation and amortization	-731	-772
Intangible assets	-2,550	-2,709
Total deferred tax liabilities	-3,281	-3,481
Valuation allowance	-4,367	-374
Net deferred tax liability	$0	$0

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Detail) (USD $)	3 Months Ended						12 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal income taxes							($3,330,000)	$2,278,000	$1,579,000
State income taxes							-567,000	390,000	270,000
Permanent items							126,000	-29,000	-24,000
Valuation Allowance							3,994,000	-374,000
Other							-223,000	406,000	216,000
Total benefit	$1,000	($1,000)	$296,000	$1,116,000	$777,000	$482,000	$0	$2,671,000	$2,041,000
Percentage of Federal income taxes							34.00%	34.00%	34.00%
Percentage of State income taxes							5.78%	5.81%	5.81%
Percentage of Permanent items							-1.29%	-0.43%	-0.52%
Percentage of Valuation Allowance							-40.75%	-5.58%
Percentage of Other							2.26%	6.06%	4.66%
Percentage of Total income tax benefit							0.00%	39.86%	43.95%

Net_Loss_Per_Share_of_Common_S2

Net Loss Per Share of Common Stock - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Net loss	($3,574)	($2,495)	($2,183)	($1,542)	($469)	($1,690)	($1,177)	($726)	($9,794)	($4,062)	($2,593)
Effective preferred stock dividend			-447	-435	-438	-430	-419	-408		-1,695	-1,589
Net loss plus preferred stock dividend-basic and diluted	($3,574)	($2,495)	($2,630)	($1,977)	($907)	($2,120)	($1,596)	($1,134)	($9,794)	($5,757)	($4,182)
Weighted average shares used to compute basic and diluted net loss per share	20,388	15,319	1,571	1,548	1,542	1,019	1,542	1,497	9,441	1,531	1,474
Basic and diluted net loss per common share	($0.18)	($0.16)	($1.67)	($1.28)	($0.59)	($2.08)	($1.04)	$0.76	($1.04)	($3.76)	($2.84)

Net_Loss_Per_Share_of_Common_S3

Net Loss Per Share of Common Stock - Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding excluded from computation of diluted shares outstanding		8,634,847
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding excluded from computation of diluted shares outstanding	1,231,886	757,805

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Collaborative Arrangement, Product PF582 [Member], Subsequent Event [Member], USD $)	1 Months Ended
	Feb. 28, 2015
Maximum [Member]
Subsequent Event [Line Items]
Development and sales-based milestone payments receivable	291,000,000
Minimum [Member]
Subsequent Event [Line Items]
Milestone payments receivable period	5 years
Up-front Payment Arrangement [Member]
Subsequent Event [Line Items]
Non-refundable upfront payment receivable	51,000,000

Quarterly_Financial_Data_Summa

Quarterly Financial Data - Summary of Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Revenues	$2,019,000	$2,801,000	$3,266,000	$2,558,000	$4,231,000	$1,989,000	$2,309,000	$3,385,000	$10,644,000	$11,914,000	$11,294,000
Cost of revenues	1,202,000	1,579,000	2,544,000	1,908,000	1,935,000	1,153,000	1,306,000	2,029,000	7,233,000	6,423,000	7,253,000
Gross profit	817,000	1,222,000	722,000	650,000	2,296,000	836,000	1,003,000	1,356,000	3,411,000	5,491,000	4,041,000
Operating expenses	4,373,000	3,698,000	2,884,000	2,173,000	3,042,000	3,635,000	2,948,000	2,563,000	13,128,000	12,188,000	8,668,000
Interest expense, net	19,000	19,000	21,000	18,000	19,000	7,000	9,000	1,000	77,000	36,000	7,000
Income tax expense (benefit)	-1,000			1,000	-296,000	-1,116,000	-777,000	-482,000	0	-2,671,000	-2,041,000
Net loss	-3,574,000	-2,495,000	-2,183,000	-1,542,000	-469,000	-1,690,000	-1,177,000	-726,000	-9,794,000	-4,062,000	-2,593,000
Effective preferred stock dividends			-447,000	-435,000	-438,000	-430,000	-419,000	-408,000		-1,695,000	-1,589,000
Net loss attributable to common stockholders	($3,574,000)	($2,495,000)	($2,630,000)	($1,977,000)	($907,000)	($2,120,000)	($1,596,000)	($1,134,000)	($9,794,000)	($5,757,000)	($4,182,000)
Net loss per share:
Basic and Diluted	($0.18)	($0.16)	($1.67)	($1.28)	($0.59)	($2.08)	($1.04)	$0.76	($1.04)	($3.76)	($2.84)
Shares used in the calculation of net loss per share:
Basic and Diluted	20,388	15,319	1,571	1,548	1,542	1,019	1,542	1,497	9,441	1,531	1,474

Quarterly_Financial_Data_Summa1

Quarterly Financial Data - Summary of Quarterly Financial Data (Parenthetical) (Detail) (USD $)	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Jul. 31, 2014
Schedule Of Quarterly Financial Data [Line Items]
Common stock issued in connection with payment of dividends	1,217,784
IPO [Member]
Schedule Of Quarterly Financial Data [Line Items]
Common stock issued in connection with payment of dividends		1,217,784
Common stock price, per share		$6
IPO [Member] \| Redeemable Preferred to Common Stock [Member]
Schedule Of Quarterly Financial Data [Line Items]
Convertible preferred stock shares converted to common stock		8,634,857
IPO [Member] \| Redeemable Convertible Preferred Stock [Member]
Schedule Of Quarterly Financial Data [Line Items]
Common stock issued in connection with payment of dividends		1,217,784

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Detail) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$44	$16	$0
Charged to costs and expenses	559	44	16
Reductions and write-offs	-18	-16	0
Ending balance	$585	$44	$16